Remission of type 2 diabetes and improved diastolic function by combining structured exercise with meal replacement and food reintroduction among young adults: the RESET for REMISSION randomised controlled trial protocol

Kaberi Dasgupta, Normand Boulé, Joseph Henson, Stéphane Chevalier, Emma Redman, Deborah Chan, Matthew McCarthy, Julia Champagne, Frank Arsenyadis, Jordan Rees, Deborah Da Costa, Edward Gregg, Roseanne Yeung, Michelle Hadjicostantinou, Abhishek Dattani, Matthias G Friedrich, Kamlesh Khunti, Elham Rahme, Isabel Fortier, Carla M Prado, Mark Sherman, Richard B Thompson, Melanie J Davies, Gerry P McCann, Thomas Yates

ABSTRACT

Introduction Type 2 diabetes mellitus (T2DM) onset before 40 years of age has a magnified lifetime risk of cardiovascular disease. Diastolic dysfunction is its earliest cardiac manifestation. Low energy diets incorporating meal replacement products can induce diabetes remission, but do not lead to improved diastolic function, unlike supervised exercise interventions. We are examining the impact of a combined low energy diet and supervised exercise intervention on T2DM remission, with peak diastolic strain rate, a sensitive MRI-based measure, as a key secondary outcome.

Methods and analysis This prospective, randomised, two-arm, open-label, blinded-endpoint efficacy trial is being conducted in Montreal, Edmonton and Leicester. We are enrolling 100 persons 18–45 years of age within 6 years’ T2DM diagnosis, not on insulin therapy, and with obesity. During the intensive phase (12 weeks), active intervention participants adopt an 800–900 kcal/day low energy diet combining meal replacement products with some food, and receive supervised exercise training (aerobic and resistance), three times weekly. The maintenance phase (12 weeks) focuses on sustaining any weight loss and exercise practices achieved during the intensive phase; products and exercise supervision are tapered but reintroduced, as applicable, with weight regain and/or exercise reduction. The control arm receives standard care. The primary outcome is T2DM remission, (haemoglobin A1c of less than 6.5% at 24 weeks, without use of glucose-lowering medications during maintenance). Analysis of remission will be by intention to treat with stratified Fisher’s exact test statistics.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ RESET will evaluate diabetes remission alongside MRI-assessed diastolic function, an early indicator of the adverse impacts of type 2 diabetes, following a low energy diet and supervised exercise.
⇒ RESET will not distinguish the impacts of the individual dietary and exercise components.
⇒ We are focusing on young adults with type 2 diabetes, a group at elevated risk for diabetes complications.
⇒ Recruitment will be challenging due to competing responsibilities and lower numbers of young persons with type 2 diabetes compared with older age groups.

Ethics and dissemination The trial is approved in Leicester (East Midlands – Nottingham Research Ethics Committee [21/EM/0026]), Montreal (McGill University Health Centre Research Ethics Board [RESET for remission 2021-7148]) and Edmonton (University of Alberta Health Research Ethics Board [Pro00101908]). Findings will be shared widely (publications, presentations, press releases, social media platforms) and will inform an effectiveness trial.

Trial registration number ISRCTN15487120.

BACKGROUND

The global prevalence of diabetes over 9% and is expected to surpass 10% by 2030. More than 90% is type 2 diabetes mellitus (T2DM).
Diabetes is diagnosed in over 8% of Canadians and 6% of persons in the UK. The Da Qing T2DM prevention trial’s 30-year follow-up demonstrated each year without T2DM translates into fewer cardiovascular disease (CVD) events. T2DM remission is emerging as a potential goal in early-onset disease, defined as an A1C below diagnostic thresholds without glucose-lowering medications.

Health behaviour-based remission trials to date have focused on meal-replacement facilitated lowering of energy intake combined with exercise counselling. The Look AHEAD (Action for Health in Diabetes) trial implemented a 1200–1800 kcal diet and an exercise target of 175 min/week. Its primary aim was reducing T2DM-related complications; remission, a secondary outcome, was 11.5% at 1 year and 7.3% at 4 years; increased fitness predicted T2DM remission. The DiRECT trial (Diabetes REmission Clinical Trial) focused on remission within 6 years of a T2DM diagnosis through an 800 kcal meal replacement diet for 3–5 months, followed by a food-based weight maintenance diet. Participants received a step counter and were advised to increase their steps. Remission was 46% remission at 1 year and over 30% at 2 years. The DIADEM-I trial (Diabetes Intervention Accentuating Diet and Enhancing Metabolism) also focused on remission, among adults within 3 years of diagnosis through a dietary strategy similar to DiRECT but with more regular exercise counselling, incorporating both time and step goals as well as a goal of resistance training twice per week. DIADEM-I achieved over 60% remission at 1 year. Our RESET for REMISSION trial combines a meal replacement-facilitated dietary intervention with a supervised exercise intervention. Such interventions in T2DM demonstrated greater glycaemic lowering than unsupervised, counselling-based approaches, with A1C lowering independent of weight loss and conferring direct cardiac benefits in T2DM. Isolated diastolic dysfunction as the earliest manifestation of the concentric remodelling that typifies diabetic heart disease. In the DIASTOLIC trial (Diabetes Interventional Assessment of Slimming or Training tO Lessen Inconspicuous Cardiovascular Dysfunction), our UK team members compared low energy meal replacement diets against thrice weekly supervised aerobic exercise training over 12 weeks among young adults with T2DM to examine impacts on cardiovascular function, with remission as a secondary outcome. Seventy percent of those in the diet arm achieved remission, without impact on diastolic function; the exercise arm had little impact on remission but improved peak early diastolic strain rate, a sensitive MRI-based diastolic function measure. In RESET for REMISSION, we will combine the dietary and exercise interventions and assess impacts not only on remission but also on A1C-based measures of cardiac function, another novel aspect of our trial. Moreover, in contrast to DIASTOLIC, we will combine supervised aerobic and resistance training to optimise lean mass preservation with weight loss, and the potential for greater reductions in A1C than those observed for supervised aerobic exercise alone. We hypothesise that this combination of a low energy meal replacement based diet and supervision for both aerobic and resistance training will have synergistic impacts on remission, enhance heart health, preserve lean mass and improve fitness.

Diastolic dysfunction is more prevalent in younger adults with T2DM compared with weight matched and lean controls. Compared with later-onset T2DM and even type 1 diabetes, young-onset T2DM has a more aggressive phenotype. Younger adults represent at least 16% of T2DM internationally. LookAHEAD studied persons 45–76 years of age and the average age in DiRECT was 53 years. DIADEM-I in contrast targeted adults 18–50 years of age. RESET for REMISSION will focus on those 18–45 years of age in cities in Canada and the UK. Even temporary T2DM remission could lead to fewer diabetes-related complications during what are supposed to be the most productive years.

Aims

Among adults 18–45 years of age with obesity, within 6 years of a T2DM diagnosis, and not on insulin therapy, we will quantify the remission efficacy of a 12-week low energy diet combined with supervised exercise, followed by a 12-week phase of weight and exercise maintenance. We define T2DM remission as a haemoglobin A1c (HbA1c) value less than 6.5% (48 mmol/mol) at 24 weeks, without use of antihyperglycaemic medications during the prior 12 weeks, concordant with the international consensus definition.

Through comprehensive cardiovascular MR (CMR), we are also assessing circumferential peak early diastolic strain rate, a sensitive measure with excellent test–retest reproducibility; end-diastolic mass to volume ratio, a marker of concentric left ventricular remodelling; and measures of aortic distensibility, a key determinant of concentric remodelling in T2DM. We will also ascertain impacts on a range of other measures (table 1) of insulin resistance, fitness, adiposity, cardiorenal parameters, diet, physical activity, mood and quality of life. We will evaluate participant perspectives (online supplemental appendix 1). Our results will guide the design of a longer-term effectiveness trial.

METHODS

Design

Prospective, randomised, two-arm, open-label, blinded-endpoint (PROBE) efficacy trial.

Setting

Leicester (Leicester Diabetes Centre), UK; Montreal (Research Institute of the McGill University Health Centre-Centre for Outcomes Research and Evaluation, Canadian coordinating site), Canada; Edmonton (Alberta Diabetes Institute—University of Alberta), Canada.

## Table 1  Outcomes

<table>
<thead>
<tr>
<th>Category</th>
<th>Week 12</th>
<th>Week 24</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcome</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes remission at 24 weeks</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Key secondary outcomes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other remission, glycaemic and insulin resistance measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes remission at 12 weeks</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Haemoglobin A1c, fasting glucose and insulin, Homeostatic Model Assessment for Insulin Resistance</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Main CMR measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left ventricular peak early diastolic strain rate (circumferential and longitudinal, MRI)</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>End-diastolic mass to volume ratio</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Main fitness measure</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VO₂ peak</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Main fat and lean mass measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total fat and lean soft tissue mass (DXA)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Weight and BMI</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Cardiometabolic indicators</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension remission, systolic and diastolic blood pressure, heart rate</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Total cholesterol, HDL, LDL, triglycerides</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Other secondary outcomes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal function measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine and estimated glomerular filtration rate</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Urine albumin to creatinine ratio</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Hepatic function measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Includes alanine aminotransferase (ALT) and bilirubin</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Depression, anxiety and distress</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital Anxiety and Depression Scale and Diabetes Distress Scale</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Indirect calorimetry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting metabolic rate</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Additional cardiac and aortic MRI-based measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Longitudinal and circumferential measures of systolic strain, end systolic volume, ejection fraction, mean T1 time</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Cross-sectional areas and distensibility of ascending and descending aortae</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Additional measures of muscle mass and adiposity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neck, hip and waist circumference</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Visceral adipose tissue, pancreatic and liver fat percentages, subcutaneous adipose tissue, muscle mass (MRI)</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>Dietary variables</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total energy and macronutrient intake (protein, carbohydrates, lipids)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Selected carbohydrate types (total sugars, starch, fibre), selected lipid types (saturated, monounsaturated, polyunsaturated, cholesterol), alcohol</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Accelerometer-based physical activity measures and sleep (daily average)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steps, overall acceleration, and intensity gradient metric</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Minutes for each of sedentary, light and moderate to vigorous physical activity</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Sleep time, duration of night, sleep efficiency (sleep time/duration of night)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Other exercise stress test measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VO₂ peak, maximum gradient achieved</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Continued
Trial time frame
We recruited the first participant on 24 September, 2021; we plan to complete recruitment by 30 June 2024 and interventions and final evaluations by 31 January, 2025.

Eligibility criteria
Adults with T2DM 18–45 years of age who were diagnosed less than 6 years previously, are not on insulin therapy, and who have a HbA1c value between 6% and 10% if taking other glucose-lowering medication or between 6.5% and 10% if not taking any glucose-lowering medications. Eligibility criteria are detailed in table 2.

Recruitment
Recruitment is primarily through clinics and family practices within the collaborative networks of participating centres and publicity through social media and other forms of media.

Run-in period
Candidates wear an accelerometer for seven consecutive days (wrist) and complete a 4-day food diary (three weekdays and one weekend day). Five days of accelerometer wear and the 4-day food diary are required to move beyond the run-in period.

Measurements
In-person evaluations occur before randomisation, at intervention period midpoint (12 weeks±1 week; no MRI study at this time point), and at intervention period end (24 weeks±2 weeks) (figure 1, table 1).

T2DM remission and related measures
The primary remission outcome requires a HbA1c below 6.5% at intervention period end, without glucose-lowering medication during the prior 12 weeks.3-6 Venous blood is sampled for HbA1c (high-performance liquid chromatography) measurement. Other related outcomes include HbA1c as a continuous variable, Homeostatic Model Assessment for Insulin Resistance and midpoint remission.

MRI-defined cardiac structure and function
Using the 3-Tesla platform30 (figure 2), we acquire cine images with retrospective electrocardiographic gating and an 18-channel phased-array cardiac receiver coil covering the left ventricle from base to apex (8 mm slice thickness, 2 mm gap with temporal resolution <50 ms and reconstructed to 30 phases). Using cmr42 software (Circle Cardiovascular Imaging, Canada), we assess end-diastolic and end-systolic volumes, ejection fraction, myocardial mass, peak diastolic filling rate, systolic global longitudinal and circumferential strain, (simplified) long axis strain, and circumferential and longitudinal peak early diastolic strain rates (figure 3).

We quantify aortic stiffness, at the pulmonary artery bifurcation with simultaneous blood pressure recording, using Java Image Manipulation (Xinapse Software, Essex, UK).29 We characterise myocardial tissue using a modified look-locker inversion-recovery sequence for a mid-level native T1 map. High native T1 time, and is a surrogate marker of diffuse interstitial fibrosis.

Adiposity and lean measurements
We measure weight (nearest 0.1 kg) and height, waist, hip and neck circumferences (nearest 0.1 cm) and use DXA (GE Lunar iDXA) for total fat and lean mass (table 1). We acquire MRI images for visceral, subcutaneous, hepatic and pancreatic adipose tissue using the chemical shift encoded (DIXON) approach. Taylor’s twin cycle hypothesis31 emphasises hepatic fat accumulation in T2DM development, leading to insulin resistance along with other metabolic dysregulations.
### Table 2 Inclusion and exclusion criteria

#### Inclusion criteria

<table>
<thead>
<tr>
<th>Category</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>18–45 years, inclusive</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>Physician diagnosis more than 3 months and less than 6 years previously</td>
</tr>
<tr>
<td>Haemoglobin A1c</td>
<td>6.5%–10%, inclusive if not taking glucose-lowering medication; 6%–10% if taking glucose-lowering medication</td>
</tr>
<tr>
<td>Body mass index</td>
<td>► 30 kg/m² to 45 kg/m², inclusive if White or Indigenous†</td>
</tr>
<tr>
<td></td>
<td>► 27 kg/m² to 45 kg/m², inclusive if other background, including mixed</td>
</tr>
<tr>
<td>Weight stability</td>
<td>Weight changes of less than 5 kg over the prior 6 months</td>
</tr>
<tr>
<td>Walking ability</td>
<td>Able to walk without assists and to participate in structured exercise training requiring the lower limbs</td>
</tr>
<tr>
<td>Capacity</td>
<td>► Able to understand written and spoken English and/or French</td>
</tr>
<tr>
<td></td>
<td>► Able to provide informed consent</td>
</tr>
<tr>
<td>Willingness</td>
<td>► Willing to be randomised and able to participate</td>
</tr>
<tr>
<td></td>
<td>► Willing to attend supervised exercise sessions, if so randomised</td>
</tr>
<tr>
<td></td>
<td>► Willing to adopt low energy diet, including abstinence from alcohol, if so randomised</td>
</tr>
<tr>
<td></td>
<td>► Willing to self-monitor glucose and blood pressure at the required frequency, if randomised to the low energy diet plus supervised exercise arm</td>
</tr>
</tbody>
</table>

#### Exclusion criteria

<table>
<thead>
<tr>
<th>Category</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other diabetes types</td>
<td>► Type 1 diabetes</td>
</tr>
<tr>
<td></td>
<td>► Gestational diabetes</td>
</tr>
<tr>
<td></td>
<td>► Monogenic diabetes</td>
</tr>
<tr>
<td>Poorly controlled blood pressure</td>
<td>Resting systolic blood pressure greater than 150 mm Hg or resting diastolic blood pressure greater than 90 mm Hg diastolic</td>
</tr>
<tr>
<td>Weight loss interventions</td>
<td>► Currently participating in a weight reduction programme in addition to routine care.</td>
</tr>
<tr>
<td></td>
<td>► Previous bariatric surgery.</td>
</tr>
<tr>
<td>Medications</td>
<td>► Insulin therapy*</td>
</tr>
<tr>
<td></td>
<td>► Use of licensed weight loss medications</td>
</tr>
<tr>
<td></td>
<td>► Significant changes in glucose lowering medications in the prior 3 months, as judged by study physicians</td>
</tr>
<tr>
<td></td>
<td>► Steroids by mouth or injection</td>
</tr>
<tr>
<td>Self-reported allergies to components of meal replacement products</td>
<td>Milk protein and/or other relevant allergies</td>
</tr>
<tr>
<td>Dietary practices</td>
<td>Dietary practices that prohibit the use of meal replacement products</td>
</tr>
<tr>
<td>Pregnancy and lactation</td>
<td>► Pregnancy</td>
</tr>
<tr>
<td></td>
<td>► Lactation</td>
</tr>
<tr>
<td></td>
<td>► Planning to become pregnant in the next 8 months</td>
</tr>
<tr>
<td>Eating disorder</td>
<td>Self-reported or diagnosed</td>
</tr>
<tr>
<td>Substance abuse</td>
<td>Alcohol, drugs</td>
</tr>
<tr>
<td>Estimated glomerular filtration rate</td>
<td>Less than 60 mL/min per 1.73 m²</td>
</tr>
<tr>
<td>Retinopathy</td>
<td>Receiving or requiring active treatment for retinopathy</td>
</tr>
<tr>
<td>Clinically manifest vascular disease</td>
<td>► Myocardial infarction</td>
</tr>
<tr>
<td></td>
<td>► Stroke</td>
</tr>
<tr>
<td></td>
<td>► Peripheral vascular disease</td>
</tr>
<tr>
<td>Other cardiac disease</td>
<td>► Heart failure</td>
</tr>
<tr>
<td></td>
<td>► Atrial fibrillation</td>
</tr>
<tr>
<td></td>
<td>► Pacemaker</td>
</tr>
<tr>
<td></td>
<td>► Implantable cardioverter defibrillator</td>
</tr>
<tr>
<td>Other conditions that could impact weight and/or safety</td>
<td>Active malignancy or other chronic disease</td>
</tr>
<tr>
<td>Run-in phase</td>
<td>► Failure to complete at least 5 or requested 7 days of accelerometer wear</td>
</tr>
<tr>
<td></td>
<td>► Failure to complete a food diary for 3 weekdays and 1 weekend day</td>
</tr>
</tbody>
</table>

*An exception is made for women who are on insulin therapy in case of pregnancy occurrence because of insulin’s established safety profile in pregnancy, rather than because of inability to control glycaemia on oral agents alone. If these women are willing and able to use a reliable form of contraception, they may be enrolled.

†Term for the original peoples of North America and their descendants; includes First Nations, Inuit and Métis peoples.
Figure 1  Trial schematic. BMI, body mass index; HbA1c, haemoglobin A1c.
with pancreatic fat accumulation that impairs beta-cell function.

Optional MRI sequences
Time permitting, optional sequences include simultaneous PROton Density Fat Fraction Imaging and Water T1-Mapping with Low B1+ Sensitivity of the liver (fibrosis), thigh (skeletal muscle volume) and heart (intramyocardial fat). In Montreal, and time permitting at other sites, we perform oxygen sensitive CMR with hyperventilation and breath-holding, enabling ischaemia/microvascular dysfunction detection without contrast. In Leicester, participants receive manganese contrast infusion, with repeated T1 mapping every 2.5 min for 30 min, to assess calcium handling.

Resting metabolic rate, fitness and strength
Following overnight fast, we conduct indirect calorimetry (ventilated hood system) for resting metabolic rate. We perform fixed speed treadmill exercise testing with increasing gradient (1% each minute) and a rolling average of 10 breaths for oxygen consumption and carbon dioxide production. The test continues to volitional exhaustion; 100% of age-predicted maximum heart rate (85% if using beta-blocker medication) plus respiratory exchange ratio ≥1.15; or ECG changes or symptoms of concern. We assess peak oxygen consumption, heart rate and blood pressure. The peak force output of handgrip is determined across three measures in each hand. We apply the Short Physical Performance Battery, WHO Disability Assessment Schedule 2.0 questionnaire and the Medical Research Council dyspnoea scale (MRC Dyspnoea Scale).

Diet, physical activity and sleep
The 4-day food diary is repeated at intermediary and final evaluations for daily intakes (table 1). In addition to run-in, participants wear an accelerometer for the 7–14 days period proximate to the intermediary and final assessments. Accelerometer data is captured at 0.075 Hz (processed through the open source R program GGIR) for daily averages of steps, overall acceleration, and intensity gradient metric, and total time at sedentary, light and moderate to vigorous intensities. Overnight wear permits capture of sleep time, night duration and their ratio (sleep efficiency).

Cardiometabolic profile
We assess seated blood pressure (automated sphygmomanometer, averaged systolic and diastolic five sequential measures). We sample blood for lipid profiles, creatinine, electrolytes and liver function tests; and urine for the albumin to creatinine ratio. Among those without RAAS inhibition for albuminuria, we assess hypertension remission at intermediary and final assessments (blood
pressure values of 130/80 mm Hg without use of antihypertensive agents during prior 12 weeks.)

Demographic factors, mental well-being and quality of life
Participants complete questionnaires on sex and gender, date of birth, ethnicity, employment, income, education, and marital status; anxiety and depression (Hospital Anxiety and Depression scale\textsuperscript{39}); diabetes-related distress (Diabetes Distress Scale\textsuperscript{40}) and quality of life (EuroQuol group 5-Dimensional 5-Level\textsuperscript{41}).

Intervention arm continuous blood glucose monitoring
To quantify the pattern of blood glucose responses to the intervention in detail, continuous glucose monitoring devices will be worn for 7–14 days preintervention, at intervention onset, midintervention and at the end of intervention, with computation of average glucose level, glucose variability (SD and coefficient of variation) and time within, above and below range.

Data gathering for process evaluation
Through a qualitative descriptive approach, we will explore experiences of intervention arm participants.\textsuperscript{42} We will use maximum variation sampling\textsuperscript{43} to capture those who did and did not achieve remission and variations in age, sex, ethnicity and location. Our individual audiorecorded and transcribed in-depth interviews (online supplemental appendix 1) are informed by the normalisation process theory framework\textsuperscript{44} and Capability, Opportunity, Motivation-Behaviour.\textsuperscript{45} Sampling will continue until saturation of themes is achieved.\textsuperscript{46}

Randomisation and allocation concealment
We randomise participants individually, stratified by country and sex, in blocks of variable size. An independent statistician developed the randomisation sequences uploaded into the Research Electronic Data Capture (REDCap) system. A researcher blinded to the sequence unveils group allocation through an autogenerated randomisation button on REDCap.

Experimental group
Full meal replacement diet for 2 weeks
Dietitian review
Participants meet with the dietitian to discuss the first 2 weeks of the intervention which include only Optifast products (Nestlé), totalling 800–900 kcal/day (30% protein, 50% carbohydrate and 20% fat). To minimise constipation, participants are recommended to drink at least 2 L of calorie-free fluid each day, and receive a fibre-based laxative, to use as needed. They are offered a digital
body weighing scale and asked to record weight weekly. They meet with the dietitian again in weeks 1 and 2 (virtually or in-person, as preferred).

**Physician review**

The study physician meets with the intervention arm participant to discuss antihyperglycaemic and antihypertensive medication withdrawal, given immediate lowering of glucose values and blood pressure with the dietary intervention. Glucagon-like peptide 1 receptors are stopped 1 week prior to the low energy diet. All other antihyperglycaemic medications are stopped the day that the diet is started. Except for ACE inhibitors or angiotensin receptor blockers prescribed for albuminuria (ie, RAAS blockade), participants stop antihypertensive medications on the day that the diet is initiated.

At weeks 1 and 2 follow-up (virtual or in-person), the physician reviews participant-recorded glucose and blood pressure data. Participants perform capillary blood glucose testing daily before breakfast and, on 1 day prior to physician follow-up, a 7-point glucose profile (measures before and 2 hours after food or meal replacement consumption and at bedtime). Antihyperglycaemic medications are not considered for reintroduction unless fasting morning capillary glucose is frequently 10 mmol/L or higher. Using the home blood pressure monitor provided, participants measure seated blood pressure each morning, after a 5 min rest period (second of two sequential measures). Antihypertensive agents are not be reintroduced unless systolic blood pressure values are generally 165 mm Hg or higher, as in the DiRECT trial. RAAS blockade may be interrupted with symptomatic hypotension.

Participants who may become pregnant are required to use reliable contraception. This is discussed, with referral as needed.

**Partial meal replacement low energy diet and supervised exercise (weeks 3–12 inclusive)**

**Exercise physiologist**

Starting at week 3, an exercise physiologist supervises 2 weekly sessions with aerobic and resistance components, at a designated facility. A third session is aerobic only, on site or elsewhere, as preferred, with self-monitoring (heart rate monitor and/or physical activity tracker provided). Participants increase exercise intensity and duration over time, with a goal of 60 min sessions.

Aerobic exercise on-site includes brisk treadmill walking (60%–80% of the maximum stress test heart rate). There is a high intensity interval walking option to maximise improvements in fitness, insulin sensitivity and lean mass preservation. With walking challenges (eg, plantar fasciitis), cycle ergometer may be offered.

Resistance training with machines or free weights includes one to three sets of four upper body exercises (bench press, seated row, shoulder press and pull down), three leg exercises (leg press, extension, flexion) and exercises targeting stability, function and posture, with a goal of 8–12 repetitions per set. At 12 repetitions with good technique, the prescribed resistance is increased. Participants are instructed in resistance band use, in preparation for the maintenance phase.

**Dietary component**

Participants shift to partial meal replacement at week 3, with 800–900 kcal daily on non-exercise days and an additional 150–200 kcal from meal replacement products on exercise days. In addition to meal replacement products, the dietary ‘real food’ components are the equivalent of 125 mL of milk (or non-dairy alternative), careful attention to adequate protein intake from foods (meat, fish, egg or alternative), 1 portion of fruit and 2 portions of non-starchy vegetables each day. Because the variety of Optifast products are more limited in Canada than in the UK, ProtiDiet (soups, oatmeal and bars) are incorporated. Participants meet with the dietitian at weeks 4 and 8. The low energy diet is continued until week 12 and/or ideal weight (corresponding to body mass index of 25 kg/m² for white participants and those of Indigenous origin and 23 kg/m² in participants of non-white or mixed background.)

**Physician review**

Participants meet with the study physician at weeks 4 and 8. The systolic blood pressure threshold to consider antihypertensive reintroduction at this stage is 140 mm Hg, as in DiRECT.

**Maintenance phase of intervention**

**Dietary component**

By week 12’s end, the dietitian and participant create an individualised plan for tapering meal replacement products, meeting again at weeks 14, 16, 18 and 21. The goal is to maintain any weight loss achieved in weeks 1–12. Meal replacement product tapering may be slowed, and product intake may even be increased again, in the event of weight regain.

**Exercise component**

Using monitoring tools, participants aim for 150 min of moderate to vigorous physical activity weekly, including three 30 min dedicated sessions at 60%–80% of the maximum heart rate. Participants may use the study exercise facility or engage in home-based or community-based exercise such as brisk walking and resistance training facilitated by bands. Participants have virtual or telephone contact with exercise physiologists at weeks 14, 16, 18 and 21. Those with less than 60 min of planned aerobic exercise and/or less than one resistance training session per week are asked to return for additional supervised sessions.

**Physician monitoring**

The study physician meets with participants at weeks 14 and 18. The thresholds for medication adjustment are as described previously. The HbA1c value at the intermediary evaluation may also be used to guide treatment.
End of intervention
Following final evaluations, intervention team members each meet with the participant to discuss strategies to maintain weight loss and exercise patterns. The study physician makes recommendations for medication management to the participant’s usual treating physician, in conformity with national diabetes management guidelines and the participant’s medication reimbursement plan regulations.

Control group
The control group receives care from their usual physician, in accordance with National Institute for Health and Care Excellence and Diabetes Canada guidelines. Following final evaluations, control arm participants will be offered a 12-week low energy diet intervention followed by a 4-week food reintroduction period.

Monitoring for adverse events
Intervention team members enquire about adverse events at each visit. Participants are asked to contact trial staff between visits to report any concerns. Serious adverse events will be reported within 7 days to all research ethics boards and the data monitoring committee, which may seek a formal adjudication of relatedness by physicians blinded to the treatment arm and who have not interacted with the study participants in question.

More common adverse events in low energy diet trials include constipation (18%–47%), headache (8%), dizziness (4%–92%), fatigue (11%–25%) and thirst (6%). Constipation responds to fibre-containing laxatives and fluid intake, and other symptoms resolve over time. In one high intensity aerobic training trial, 16% experienced fracture or lower extremity muscle cramping and/or muscle, ligament, or tendon strain; 5.2% experienced chest pain, difficulty breathing, dizziness or loss of consciousness. In a trial with a combined resistance and aerobic exercise arm, 12.5% had one of shoulder injury, left knee pain, spinal stenosis exacerbation or hip pain; one participant experienced atrial fibrillation.

Withdrawal
Interventions and evaluations are halted in the event of intolerance to the study intervention or an adverse event that precludes participation, prolonged or serious hospital admission, the development of a serious comorbid condition such as active malignancy or pregnancy. We will document reasons for participant-initiated withdrawal, if specified.

COVID-19 restrictions and adaptations
If COVID-19 restrictions are resumed, exercise physiologist led sessions using video conferencing may be used to replace some in-person supervised exercise sessions, using heart rate monitors, self-monitoring devices and resistance bands. Any remaining in-person intervention visits or outcome measurement sessions will be undertaken using personal protective equipment following clinical guidelines that are current at the time of practice.

Sample size
In the DIRECT trial, remission was 46% at 1 year (vs 4% in control arm; OR 19.7). Even higher remission was observed over the shorter term in other studies. We initially allowed for a minimum 45% remission at 24 weeks in the intervention group and up to a 5% remission rate in the control group. Using a Fisher’s exact test with 90% power, a significance of 0.05, and a 1:1 ratio between intervention and control groups, we estimated needing 56 individuals to complete the trial (control=28, intervention n=28). Allowing for up to 30% drop-out, we planned to recruit 80 individuals in total (40 UK, 40 Canada) in our successful application for funding to the MRC and the Canadian Institutes of Health Research.

We subsequently obtained additional funding from the Canadian JR McConnell Foundation, and increased recruitment goals in Canada from 40 to 60 participants (40 UK, 60 Canada). With an overall sample size of 100 (40 UK, 60 Canada), if 70 (70%) complete the trial, we will have 90% power to detect a minimum 35% remission at 24 weeks in the intervention group and up to a 5% remission rate in the control group.

Retention of at least 35 participants in each arm (70 total) will provide over 80% power to detect a difference in mean peak early diastolic strain rate of 0.10/s difference, equivalent to the exercise effect in the DIABETIC trial (see BACKGROUND), assuming that the common SD is 0.144 as in the DIABETIC trial and using a two group t-test with a 5% two-sided significance level.

Statistical analyses
Our primary outcome measures the proportion of remission in the intervention arm relative to the control arm. We will apply intention-to-treat principles for the primary outcome, assuming that remission of diabetes did not occur if information is not available. Based on the DiRECT and DIABETIC-I trials, we estimate that remission counts in the control arm could be less than 2. We will therefore use stratified Fisher’s exact test statistics (ie, stratification by country and by sex) if remission counts are low in the control arm but consider Pearson χ² test, if appropriate. If numbers permit, logistic ORs with 95% CIs (exact method) will also be performed to further quantify the efficacy of intervention over the control group, after adjusting for factors used to stratify the randomisation (country, age or sex); we will not have missing values for these covariates. Subgroup analyses for the primary outcome will be performed by country, sex and the degree of weight loss (<5%, 5%–10%, 10%–15%, >15% as examined in the DiRECT trial, collapsing categories as needed, and by exercise adherence (<50%, >50% of supervised sessions attended). In a per-protocol analysis, we will restrict the intervention group to those who achieved at least 10% wt loss and adhered to at least two thirds of prescribed exercise sessions.

We will analyse dichotomous secondary outcomes (eg, diabetes remission at 12 weeks, hypertension remission at 12 and 24 weeks) as described for the primary outcome.
We will analyse continuous key secondary outcomes (eg, left ventricular peak early diastolic strain rate, lean soft tissue mass) through linear regression or log-linear regression, as appropriate, with stratification by country and sex.

**Process evaluation analyses**

At least two trained team members will independently code transcripts for themes, continually refining existing codes and identifying new ones. We will use Dedoose V.7.0.23 and NVivo analysis software to facilitate data coding/organisation.

**Data management**

Data management is facilitated by institutional REDCap systems, with access controlled through Active Directory Technology. Data and images shared across participating centres use secure data transfer systems with all identifiable information removed. Within REDCap, we have derived plausible ranges for all outcome measures; values outside these ranges are automatically flagged and verified for accuracy.

**DISCUSSION**

Low energy diets incorporating meal replacements can achieve T2DM remission through weight loss, but may reduce lean mass. Exercise can preserve lean mass and directly lower insulin resistance. Combined aerobic and resistance training yields additive glucose-lowering benefits. Regular exercise reduces CVD events and improves MRI-based measures of heart health. RESET for REMISSION will quantify remission of T2DM in young adults achieved through a combined low energy diet and supervised aerobic and resistance training intervention and will also ascertain changes in diastolic function, lean mass and other factors that may impact long term outcomes.

Since funding was awarded for RESET for REMISSION, the literature has continued to evolve, with publication of the DIADEM-I trial, which targeted remission in younger adults less than 50 years of age of West Asian or North African ancestry. DIADEM-I combined a low energy diet (800–820 kcal/day) with exercise prescription from a trained professional centred on walking activities and self-monitoring tools, with resistance exercises introduced as the intervention progressed. While this trial did not include supervised exercise training, the objective measurement of physical activity, or cardiac function and structure, it does provide robust evidence that a low energy diet combined with physical activity can be combined in younger adults with T2DM while leading to an equivalent level of remission as has been shown in older populations, such as DiRECT.

While young persons with T2DM stand to gain the most from remission, their daily life demands may render recruitment and adherence challenging. We have endeavoured to mitigate this by integrating virtual communication tools for monitoring and follow-up where possible. Recruitment itself may be challenging in these younger individuals, as they remain fewer in number than middle-aged and older individuals with T2DM. We are, therefore, collaborating with a wide network of practices and drawing on other diabetes research cohorts in which participants have provided permission to be contacted for trials.

The international diabetes remission panel underscored the importance of evaluating the impacts of non-glycaemic measures during remission. RESET evaluates not only lipid profiles and MRI measures of pancreatic, hepatic and visceral fat but also sensitive MRI-based indicators of heart health for a comprehensive picture of intervention impacts. Equally importantly, we seek to understand impacts on quality of life, diabetes distress and mood.

The Canada-UK collaboration that underpins our trial will allow a wider sharing of knowledge and perspectives than in a single-country study, challenging all to learn from best practices in each jurisdiction. The DiRECT trial led to an ongoing 5000 person pilot by the National Health Service in the UK for prescribing meal replacements as part of routine T2DM management. The visibility of the current trial and the Canada-UK partnership could be an important step towards considering implementing such an intervention with integration of exercise in Canadian healthcare jurisdictions. Indeed, a future trial may seek partners beyond these two countries, to move from a demonstration of efficacy to one of effectiveness across a wide range of settings, and a plan for implementation. This is a critical journey not only to meet the glycaemic definitions of diabetes remission but also to establish its potential myocardial and vascular effects.

**Sponsors**

The study is sponsored by the University of Leicester in the UK (RGOsosponsor@leicester.ac.uk) and the Research Institute of the McGill University Health Centre in Canada (gilbert.tordjman@mhc.mcgill.ca) who will ensure the study is conducted according to Good Clinical Practice and that all contractual, governance, ethics and regulatory processes are followed.

**Trial steering committee**

This committee is responsible for the overall oversight of the trial and will review and approve protocol amendments, any substudy proposals, and will review recruitment rates, protocol adherence, retention, compliance, safety issues, planned analyses and reports, and will act on recommendations of the data monitoring committee. The trial steering committee includes an independent chair (Jason Gill, University of Glasgow), an independent clinician (Alice Cheng, University of Toronto), the Nominated Principal Investigators (Kaberi Dasgupta, McGill University and Thomas Yates, University of Leicester), the key site investigator in Edmonton (Normand Boulé, University of Alberta) and the trial statistician (Elham Rahme, McGill University). The trial steering committee’s
operations are described in its charter (online supplemental appendix 2).

Data monitoring committee
The data monitoring committee is responsible for the interests and safety of the participants and its main role will be to make advisory recommendations to the trial steering committee. It includes an independent clinician (Andrew Farmer, Nuffield Department of Primary Care Health Sciences, University of Oxford), an independent chair (Janusz Kaczorowski, University of Montreal) and independent statistician (Stephen Sharp, University of Cambridge). The data monitoring committee is independent from the sponsors and operates in conformity with a charter (online supplemental appendix 3).

Patient and public involvement
This group will provide feedback throughout the trial on recruitment, evaluation, and retention strategies and alternatives. They will be involved in interpretation of findings and knowledge dissemination efforts, including manuscript coauthorship, presentations and interviews. The partners in Canada include Josette Spencer, Mark Marcinkiewicz and Sylvie Lauzon, who is Executive Director of Diabetes Quebec. Patricia Kearns is a patient partner trainer who assisted with training of the patient partners. Alastair Masters is a patient partner based in the UK.

DISSEMINATION
We will publish the results of this trial in peer-reviewed journals and disseminate further in the scientific community through educational and conference presentations and social media targeting health professionals and the scientific community. We will share findings with the general public through press releases, media interviews and social media forums. The trial patient partners and participants will be invited to assist with knowledge sharing, including media interviews and op-eds.

Author affiliations
1Department of Medicine, McGill University and Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
2Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada
3Diabetes Research Centre, University of Leicester and NIHR Leicester Biomedical Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK
4School of Public Health, Imperial College London, London, UK
5Division of Endocrinology & Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
6Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK

10Courbis Cardiovascular Signature Centre, McGill University Health Centre and Departments of Medicine and Diagnostic Radiology, McGill University, Montreal, Quebec, Canada
11Diabetes Research Centre, University of Leicester and NIHR Applied Research Collaboration - East Midlands (ARC-EM), University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK
12Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada
13Department of Medicine, McGill University, Montreal, Quebec, Canada
14Department of Biomedical Engineering, University of Alberta, Edmonton, Alberta, Canada

Twitter Abhishek Dattani @A_Dattani07

Contributors KD and TY are the principal investigators of the trial and led the design and writing of this protocol, with critical input from coinvestigators NB and JH, particularly related to the exercise intervention and fitness and strength evaluations; SC, ER, FA and CMP, experts in nutrition and body composition measures; GPM, MGF, RBT and AD, experts in MRI-based assessments of cardiac function and ectopic fat; DDC and MH, related to health coaching and process evaluation; MM, DC, JC and JR as related to trial logistics and procedures; MJD, MS and RY, with important input on medication management; EG and KK, for comments on recruitment and overall procedures; ER, as related to statistical considerations; and IF, with respect to the data management plan.

Funding The primary funders of this trial are the Medical Research Council (MR/T031816/1) of the UK and the Canadian Institutes of Health Research (JCD-170584; Institutes of Musculoskeletal Research and of Nutrition, Metabolism & Diabetes), organisations that have contributed equally to this endeavour. Additional funding in Canada was obtained from the John R McConnell Foundation to support additional enrolment in Canada, as previously described. Support for intervention delivery at the UK site is provided by the NIHR Leicester Biomedical Research Centre and Clinical Research Network. For the Canadian sites, some capillary glucose meters and strips were donated by Roche Diabetes Care (Canada) and continuous glucose monitoring supplies by Dexcom (San Diego, California, USA)

Disclaimer The sponsors and funders have no direct role in study design, data collection, management, analysis, interpretation of data, report writing or publications that arise from the trial.

Competing interests MGF is board member, shareholder, and consultant of Circle Cardiovascular Imaging. Through the University Hospitals of Leicester NHS Trust, coinvestigator GM has a research agreement with Circle Cardiovascular Imaging. We will be using software from this company to analyse the cardiac MRI images that we will obtain. KK has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, Takeda, Servier, and Pfizer and research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, and Pfizer. MJD has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi, Lilly and Boehringer Ingelheim, an advisory board member and speaker for AstraZeneca, an advisory board member for Janssen, Lexicon, Servier and Gliead Sciences and as a speaker for Napp Pharmaceuticals, Mitsubishi Tanabe Pharma and Takeda Pharmaceuticals International. She has received grants in support of investigator and investigator initiated trials from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, AstraZeneca and Janssen. TY has received investigator initiated funding for obesity-related research from AstraZeneca.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
REFERENCES


Type 2 diabetes in adults: management NICE guideline [NG28], 2015. Available: https://www.nice.org.uk/guidance/ng28


Type 2 diabetes in adults: management NICE guideline [NG28], 2015. Available: https://www.nice.org.uk/guidance/ng28


**Appendix 1.** Interview guide for in-depth interviews with intervention arm participants at completion of final evaluations

This topic guide is a flexible tool and may be revised as new areas of interest arise during the process of data collection. The wording of the question is for guidance only and can be varied to suit the natural style of the interviewer and the level of understanding of the participant. This topic guide will be adapted to use for those who are involved in this study.

The interviewer will be a trial team member who has not interacted with the participant during the course of the trial. The interview may be conducted in person, by video teleconference, or by telephone, as preferred by the participant.

**Introductory remarks**

The interviewer will iterate that the purpose of the interview is to:

- Explore the participant’s knowledge, views and experience of the RESET trial interventions

Participants will be assured that:

- They are not being ‘tested’ – there are no right or wrong answers.
- They are free to say as much or as little as they want.
- Their specific comments will be anonymously quoted in manuscripts and reports. Individual comments will not be shared with anyone external to the research team.

Recording will be started after introductory remarks.

**Questions to discuss**

1. What made you want to participate in this study?
2. When you started, did you feel you were you prepared to invest time and effort to make the intervention work?

3. When you were assigned to the ‘active intervention’ group, what was your understanding of how the intervention could benefit you?

4. What are your thoughts about this programme overall? Probe: What did you think about the format? The length of the sessions? What did you find easy to do? What was difficult?

5. Were you able to attend the sessions? Probe: if participants respond no, probe reasons for not being able to attend.

6. Was the venue convenient for the exercise training? (i.e. easy to attend) If not, what would have helped to make the venue convenient to you?

7. Dietary component:
   
   7a) What was your experience with the dietary support sessions? Prompt: meal replacement products, dietary support sessions, limited amounts of food

   7b) How did you find the reintroduction to food? Prompt: questions around pace, was it manageable, did they require more support etc.

   7c) Can you tell us if you felt the sessions helped in any way to manage your diet? Probe in what way do you feel this has helped, or has not helped?
8. Exercise component:

8a) You took part in exercise training (combined aerobic and resistance activities) – Can you tell me a little bit about this? Prompt: difficulty, convenience, motivation, challenges in combination with diet

8b) How well were you able to exercise independently once the close supervision of the first 12 weeks ended? Prompt: Challenges, need for return to supervision

8c) Can you tell us if you felt the sessions helped in any way to manage your exercise training? Probe: in what way do you feel this has helped, or has not helped?

9. Medication adjustments, glucose and blood pressure:

9a) How did you feel about stopping some medications at the beginning of the program? Probe: What concerns, if any, did you have?

9b) How did you feel about your glucose levels and blood pressure levels during the program? Probe: Did you feel that you were well-monitored during this period?

10. Did you make any changes in your eating? Probe: If yes, when you were making your diet changes, did you feel you were making a difference to your health?

11. Did you make any changes in your exercise? Probe: If yes, when you were making your exercise changes, did you feel you were making a difference to your health?

12. What skills do you feel you have taken from taking part in the intervention?

13. Diet component

13a) Were there any tasks or time constraints that would influence your ability in making changes to your diet? Elaborate
13b) What factors would you say influenced whether you were able to maintain your diet plan?

14. Exercise component

14a) Were there any tasks or time constraints that would influence your ability in making changes to your exercise? Elaborate

14b) What factors would you say influenced whether you were able to maintain your exercise plan?

15. Did you ever discuss the programme with your family members or friends? Probe: What did they think of your participation? Were they supportive? Concerned? Were they sceptical?

16. Would your family members or friends influence what you did as part of the programme? If so, to what extent? Prompt: i.e. was their influence positive? Was it negative?

17. Do you feel the intervention affected your relationships in any way? Prompt: i.e. by not eating regular food based meals with the family

18. If you made changes to your eating or physical activity, how important do you think it is for you to maintain these changes to your health? (elaborate why this is or isn’t important to the participants)
19. How optimistic are you about maintaining these changes to your health? Prompt: if not optimistic, explore the reasons why

20. If there was additional support available in the intervention, what would this be?

21. What would you do differently if you were asked to take part again?

22. Do you have any suggestions for improving the programme?
INFORMATION AND CONSENT FORM

Research Study Title: REMISSION OF DIABETES AND IMPROVED DIASTOLIC FUNCTION BY COMBINING STRUCTURED EXERCISE WITH MEAL REPLACEMENT AND FOOD REINTRODUCTION IN ENGLAND AND CANADÁ: THE RESET FOR REMISSION TRIAL

Protocol number: 2021-7148

Researcher responsible for the research study: Dr. Kaberi Dasgupta, Professor of Medicine and Physician, MUHC; Scientist, Research Institute of the MUHC

Co-Investigators: Dr. Stéphanie Chevalier, Associate Professor of Medicine and Scientist, Research Institute of the MUHC
Dr. Deborah Da Costa, Associate Professor of Medicine and Scientist, Research Institute of the MUHC
Dr. Elham Rahme, Associate Professor of Medicine and Scientist, Research Institute of the MUHC
Dr. Matthias G. Friedrich, Professor of Medicine and Radiology and Physician, MUHC
Dr. Isabel Fortier, Assistant Professor of Medicine, MUHC; Scientist, Research Institute of the MUHC
Dr. Mark Sherman Associate Professor of Medicine and Physician, MUHC

Funding source: The Canadian Institutes of Health Research (CIHR)

Sponsor: The Research Institute of the MUHC

INTRODUCTION
We are inviting you to take part in this research study because you were diagnosed with Type 2 diabetes less than 6 years ago.

However, before you accept to take part in this study and sign this information and consent form, please take the time to read, understand and carefully examine the following information. You may also want to discuss this study with your doctor, a family member or a close friend.

We invite you to speak to the researcher responsible for this study ("the researcher") or to other
members of the research team and ask them any questions you may have about this study. Please also ask a member of the research team about any parts of this consent form you do not understand.

BACKGROUND
More and more people are getting type 2 diabetes. They are also getting it at younger ages (aged between 18-40 years) than in the past. This is worrying because heart, kidney and physical fitness problems related to diabetes can therefore also happen at an earlier age than in the past.

Past studies show that diets with a low number of calories can make blood sugar levels go back to normal without diabetes medications in people who have had type 2 diabetes for just a few years. This is called ‘reversing diabetes.’ A low calorie diet means eating a lot less than normal for some weeks often with special shakes and meal bars, with the guidance of a dietitian. Once people have lost enough weight, they can start to eat more regular food again while trying to keep off the weight they may have lost.

Exercise, such as walking and simple muscle building activities, can also make your blood sugar levels better and help your heart and muscles work more efficiently. Putting a low calorie diet together with a supervised exercise program has not been studied before to look at how well it works in reversing diabetes and improving how the heart and muscles work.

PURPOSE OF THE RESEARCH STUDY
The main goal of this study is to see whether combining exercise and a low calorie diet can reverse diabetes and make the heart and muscles work better.

This study is a randomized trial. This means that if you agree to participate in this study, you will be randomly assigned to one of two groups based on chance, like rolling a dice or flipping a coin. The two groups in this trial are:

- Group 1: usual standard care (that means continuing to be treated as you are right now)
- Group 2: a combination of an exercise program and a low calorie diet.

Neither you nor the researchers can choose the group to which you will be assigned. We will not know in which group you will be assigned until the trial begins. Both groups will have a series of tests and questionnaires at the beginning, middle, and at the end of the study, so we can compare the groups and what happens to them.

For this research study, we will recruit 30 to 35 people in Montreal. They will be men and women, between 18 and 40 years of age.

DESCRIPTION OF THE RESEARCH PROCEDURES
This research study will take place at the McGill University Health Centre. During the study, the research staff may communicate with you via e-mail, cell phone texting (standard text message rates apply) or video call.
Your participation in this research project will last 6 to 7 months and will include on-line questionnaires and at least 5 visits for testing (both Group 1 and Group 2). For those who are in the Group 2 (structured exercise with low calorie diet group), there will be more visits for counselling and supervision. Before we ask you to answer questionnaires or schedule visits, the study doctor will first go through your medical records and may talk to your doctor to make sure that you are eligible for the study. If you are eligible, we will ask you to complete the steps below.

1. Duration and number of visits
You will first complete an on-line questionnaire, an on-line 4-day food diary, and 1 week of physical activity monitoring with a device worn on your wrist. A paper-based alternative to the diary and questionnaires is also available, if you prefer. If you complete these procedures, you will be scheduled for the first two visits (visit 1 and visit 2 described in the table below). The study doctor will review the results of the first two visits to confirm that it is okay for you to continue the research. If it’s okay, then we will do the randomization (like ‘flipping a coin’) to decide which of the two study groups you will be in.

2. Description of the trial groups and related procedures

GROUP 1- Standard care
If you are in the standard care group, you will receive your normal diabetes care. You will also be given a leaflet about the benefits of diet and exercise. You will come back for VISITS 3, 4, and 5, as described above. If you complete all visits, you will be offered the low calorie diet at the end of the trial, in thanks for your participation.

GROUP 2- Low calorie diet and structured exercise
Glucose and blood pressure medications and study physician supervision
We will stop your diabetes and most blood pressure medications at the beginning of the diet and exercise program. This is because the low calorie diet and the structured exercise will probably lower your blood sugar and blood pressure quite a lot. To be safe, we have to stop the medications.

A study doctor will see you at the beginning of the study and will stay in contact with you throughout the 24 weeks to monitor your blood sugar and blood pressure and decide with you if any medications need to be restarted. You will be asked to monitor your blood glucose more often. For study purposes, we will lend you a home blood pressure monitor and a weighing scale and provide you with glucometer strips if you do not have enough to measure your glucose levels at home.

You will measure your glucose levels, blood pressure, and body weight at home, and report these back to the study physician, dietitian, and exercise specialist, as they instruct. In general, you will be asked to check your glucose level every day before your first meal and 7 times the day before each time you meet with the study doctor (before and 2 hours after each ‘meal’ and at bedtime), your blood pressure when you wake up in the morning, and your body weight at least once each week. You will be measuring your glucose levels during the study with the usual way of pricking your finger with a lancet, placing a drop of blood on a test strip, and inserting the strip into a glucometer. You will measure your blood pressure with the monitor that we lend you during the study. You will sit comfortably with your back supported, attach the blood pressure cuff (like a band) on your upper arm, and rest for about 5 minutes. You will
then press a button to start the reading. Once the reading is done, you will push the button for a second reading, and this is the reading you will write down. You will write the blood pressure (first number and second number), body weight, and glucose values into an online diary that you and the study physician, dietitian, and exercise physiologist will be able to access. If you prefer, we can give you a paper diary instead. We will give you a fibre-based laxative (Metamucil) to take when needed in case you become constipated while on the low calorie diet described below.

We emphasize that it is very important not to become pregnant during the study. With this in mind, if you are female, the study physician will review your use of reliable contraception throughout the study. If you become pregnant, all study interventions will be stopped.

The low calorie diet
This diet will be a major change in your life for 12 weeks. You have to be aware of what is involved. You will have regular support from a study dietitian. This will be face to face or through telephone calls or virtual meetings.

Part 1 (2 weeks). You will have a “total dietary replacement” where you only consume special shakes and lots of water. The shakes will give you around 900 calories each day. All of the shakes will be free of charge and will be give to you the first time you meet the dietitian, which will be face-to-face at least the first time.

Part 2 (10 weeks). After the first two weeks, you will eat one meal with regular food each day. The rest of what you eat will be meal replacement products like the shakes you had the first two weeks. To give you more variety, on top of shakes, you will also get special soups and bars. On most of the days each week (4 out of 7 days), you will still have about 900 calories each day (all of the meal products and the one meal each day all considered together).

During this ‘part 2’ time, you will also be exercising 3 days each week. On the days that you exercise, you will have some extra meal replacement product so on those days you will be taking in a bit more than 900 calories.

You and the dietitian will figure out together what kinds of meals you will eat to make sure that you are not taking in more calories than the limit set by the study. She will work with you to pick foods that you prefer. She will also help you figure out what combination of shakes, bars, and soups you might like best.

Part 3 (12 weeks). At this point, you will probably have lost weight and we will now try to help you keep it off. Even if you have not lost weight, we will help you transition back to a healthy food-based diet. The dietitian will help you bring back normal foods. She will calculate about how many calories you will need every day to keep your weight the same as it is at 12 weeks. We will support you to figure out portion sizes and food choices. The goal is to help you keep off the weight you have lost. If you gain weight, she will reintroduce or increase some meal replacement products and remove some regular meals from your plan, for a period of time.
The structured exercise program
The exercise program will start after your first two weeks of shakes. We don’t want to overwhelm you with too many changes at once, so we will start the exercise program at the same time that you get one food meal back in your diet at week 3.

Just as the dietitian supervises you in the low calorie diet part, an exercise specialist (exercise physiologist) will supervise you in the exercise part. The sessions are free of charge.

Part 1 – During the first 2 weeks when you are having the shakes only diet, you will continue with your usual activities.

Part 2 – During the next 10 weeks you will exercise, you will have two supervised exercise sessions at the PERFORM Centre, located at 7272 Sherbrooke Street West. You will take part in lots of different exercises designed to increase your fitness and strength. The planned exercise will take into account your level of fitness and ability. You will use a treadmill, free weights, bands, and weight machines. The exercise specialist will help you use these safely and effectively. The specialist will design a third session for you to do each week. This ‘unsupervised’ session can be done outdoors, at another gym, or at home but you will also have the option to come to PERFORM for this, to access the equipment and facilities. Please note, however, that if there are any government-mandated COVID restrictions in place, the PERFORM gym will not be available for unsupervised exercise. You will wear a Fitbit device that we will lend you so that you and we can monitor your unsupervised exercise and activities of daily living.

Part 3 – During the next 12 weeks, you will exercise on your own. The goal is for you to keep exercising at the level and amount that you have been doing in part 2. The exercise specialist will make a plan with you and will be checking in with you by phone, text, or e-mail. If you are having difficulty or are not exercising regularly, you will be asked to return for some supervised sessions. When you are exercising on your own during these 12 weeks, you will still have the option of exercising at the PERFORM Centre. As we state above, however, if there are any government-mandated COVID restrictions in place, the PERFORM gym will not be available for unsupervised exercise. You will wear a Fitbit device that we will lend you to track your aerobic exercise and physical activity.

Additional glucose sensors
As we talked about above, you will be testing your blood sugar levels at least once a day at home and 7 times on the day before you have a visit with the study doctor. You and the study doctor will know all of these numbers. On top of that, we will measure your glucose levels throughout the day using a special device called a continuous blood glucose monitor (CGM). The study physician won’t use the CGM numbers to guide you; she will stick to the numbers you measure yourself at home. We will use the CGM numbers for research analysis (‘research math’) to understand overall the patterns of blood sugar change in the two study groups. The research team will download and store these numbers for analyses.

We will show you how to place the CGM sensor on the skin of your upper arm. It has a small filament that is inserted under your skin with a small needle (less than 1 cm long). The needle is then removed and only the flexible filament remains under your skin. We will show you how to tape the sensor to
your arm. You can shower with it. Once in place, you do not need to do anything else with it. The CGM sensor measures your blood glucose continuously and stores values every 15 minutes.

We will ask you to wear a CGM sensor at 4 different time points, each time for two weeks. These are the 4 time blocks:

(1) The week before you start the low energy diet and the first week of the low energy diet;
(2) The second week of the low energy diet and the first week supervised exercise is added;
(3) The 11th and 12th weeks after you start the diet, when we should start seeing the strongest effects of what you are doing;
(4) The 23rd and 24th weeks when you are finishing up the study.

Each time you put on one of these sensors, you will mail it back to us after two weeks in a stamped envelope we will give you or you will bring it to the PERFORM centre where we will collect it from you.

3. Tests and procedures

After you agree to join the study, we will ask you to do the following:

<table>
<thead>
<tr>
<th>Accelerometer to monitor your activity &amp; sleep) for 7 days</th>
<th>We will mail you a small machine to wear on your wrist called a research accelerometer. This measures how much time you spend sleeping, sitting and moving. It can be worn all day and night. We will ask you to wear it for 7 days. You will then mail it back to us in the postage paid envelope that we will give you.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food diary</td>
<td>We will explain to you how to log onto an online food diary or mail you a paper one to complete. We will ask you to track what you eat over 4 days (three weekdays and one weekend day). If you complete a paper diary, you will mail it back with the accelerometer. This will help you understand what your food habits are.</td>
</tr>
<tr>
<td>Questionnaire – done at home</td>
<td>We will ask you to fill out an online questionnaire (or paper version, if you prefer). You can reach our study staff by phone or email to answer any questions you have. You also have the option of answering the questions by phone and the staff can fill in the answers for you. Examples of what the questions will be about are feeling anxious or depressed, how well you function in your day to day life, history of illness in your family, your cultural or ethnic background, any trouble breathing, how much schooling you completed, the kind of work you do if you are employed, and whether or not you have a partner. We will also ask female participants about previous pregnancies. We estimate that these questions will take about 20 minutes to complete.</td>
</tr>
</tbody>
</table>

If you do not complete the above procedures, you will not be invited to continue in the study. Once you complete the above procedures at home, you will be scheduled for some face-to-face visits for evaluation.
The study doctor or a member of the research team will conduct the following tests and procedures:

<table>
<thead>
<tr>
<th>Procedures at visit 1, 3 and 4 (fasting)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preparation for visits 1, 3, and 4 (fasting)</td>
<td>To make sure we have accurate results on the tests we are doing, we ask you not to exercise or drink alcohol for two days before you come to see us. We also have to ask you to fast and not smoke the night and following early morning (about 10 hours total) before you come in to have accurate results on blood tests. Do not take your diabetes medications until we give you a snack later in the morning before the exercise test. You can take the other medications that you would normally take at that time of day.</td>
</tr>
<tr>
<td>Urine collection</td>
<td>We will ask you to go to the washroom to empty your bladder into a container that we will give you. We will use the urine sample to check how your kidneys are working. If you are a woman who is able to become pregnant, we will do a urine test for pregnancy before you start participating in the study. We will ask you to put on a hospital gown.</td>
</tr>
<tr>
<td>Height, weight, neck, waist and hip measures</td>
<td>We will ask you change into a hospital gown. We will weigh you (in the gown without shoes) and measure your neck, waist, hip and height.</td>
</tr>
<tr>
<td>Indirect calorimetry</td>
<td>This test will tell us how much energy you use when you are still. It reflects the amount of energy your body uses to keep your blood flowing and your organs working. You will lie still on a table under a clear hood, staying awake. A machine connected to the hood will measure how much oxygen you are breathing in and how much carbon dioxide you are breathing out.</td>
</tr>
<tr>
<td>Review of your medications</td>
<td>You will bring in a list of your medications (with doses) or the medication containers themselves. These will be noted down by study staff. They will ask you some more questions about your medical history and current health.</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>We will ask you to sit down quietly for 5 minutes. We will then take one measure from the left arm and then the right arm. Then six measures will be taken 1-minute apart in the arm that had the higher value on the first measurement.</td>
</tr>
<tr>
<td>Bioelectrical Impedance Analysis (BIA) test</td>
<td>This test will estimate your body fat and ‘lean’ mass (muscle) by running a small electrical current through the body that you will not feel. You will stand on the machine and hold onto the bars.</td>
</tr>
<tr>
<td>Blood collection</td>
<td>We will take some blood (about 34 mL or roughly 7 teaspoons) to measure the amount of sugar and fat in your blood and other blood tests related to type 2 diabetes and the heart.</td>
</tr>
<tr>
<td>Fitness test</td>
<td>We will give you a snack (or if this is visit 3, a lunch) before the fitness test.</td>
</tr>
</tbody>
</table>
You will be walking/running on a treadmill. The speed will remain the same but the incline of the treadmill will slowly increase. We will ask you to keep going as long as you can to figure out how fit you are. It will feel feel like climbing up a hill that gradually becomes steeper and steeper. You will be asked to breathe through a mask in order to collect and measure the carbon dioxide you breathe out and the oxygen you breathe in.

<table>
<thead>
<tr>
<th>Procedures at visit 2 and 5</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preparation for Visits 2 and 5</strong></td>
<td>Please do not smoke, consume caffeine-containing beverages or foods (coffee, tea, cocoa, chocolate, “energy drink” or cola) for 12 hours before MRI visit and do not eat for 4 hours before the MRI Visit. If you are on a type of medication for blood pressure called a beta-blocker, they study doctor will ask you to not take it 12 hours before the MRI.</td>
</tr>
<tr>
<td><strong>MRI</strong></td>
<td>Magnetic Resonance Imaging (MRI) is an imaging method that uses a magnetic field with radio frequency waves, which allows doctors to see your organs inside your body. Before your scan, we will figure out if you have been taking a medication called a beta-blocker for high blood pressure; if yes, on the day of the scan, we will ask you to delay taking it until after the can. During the scan, you will lie on your back inside the scanner. The inside of the machine is quite small. Some people may start to feel claustrophobic. When the scanner is working, it makes loud buzzing sounds. Therefore, you will wear headphones. We will use the scanner to take pictures of the heart. We will also measure how much fat you have in and around your organs. The MRI will produce images and the computer will collect this information. Some images will require for you to hold your breath for a short period of time (2-15sec) and the technologist will give you specific instructions. It is very important that you don’t move when the picture is taken, as this can blur the pictures. Your heart, blood pressure, and blood oxygen levels will be closely monitored during the test. Electrocardiogram (ECG) electrodes (stickers) will be placed on your chest. A blood pressure cuff will be placed around your upper arm. A pulse oximeter (a small device to measure the amount of oxygen in your blood) will be attached to one of your fingers.</td>
</tr>
<tr>
<td><strong>DXA (Dual Energy X-ray Absorptiometry) scan</strong></td>
<td>This test uses X-rays to measure the overall amount of fat and muscle you have in your body. We will also ask you to stay as still as possible. You will lie on a padded table. There will be a machine that makes X-rays below the table. There will be a moveable machine ‘arm’ above the table that detects the X-rays. The arm will move across your body above you.</td>
</tr>
<tr>
<td><strong>Physical function tests</strong></td>
<td>After a snack, you will do a few tests that will measure hand grip strength, balance, time it will take you to walk 4 metres and time it takes for you to rise from a chair.</td>
</tr>
</tbody>
</table>
The schedule of procedures for each visit is listed below:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Prior to visit 1</th>
<th>Visit 1</th>
<th>Visit 2</th>
<th>Visit 3</th>
<th>Visit 4</th>
<th>Visit 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of in-person visit (hrs:min)</td>
<td>At home</td>
<td>4:00</td>
<td>2:10</td>
<td>5:30</td>
<td>4:30</td>
<td>2:10</td>
</tr>
<tr>
<td>Timeline</td>
<td>Done within 14 days of visit 1</td>
<td>12 weeks after visit 1</td>
<td>24 weeks after visit 1</td>
<td>24 weeks after visit 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine test</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height, weight, neck, waist and hip measures</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indirect calorimetry test</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy test (if necessary)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medication list review</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioelectrical Impedance Analysis (BIA)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting, blood test</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Snack given to participant</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lunch given to participant</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fitness test</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wear a device to monitor your activity &amp; sleep</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Food diary</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Online questionnaire (at-home)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DXA</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Snack given to participant</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical function test</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For those in the Group 2 (low calorie diet and exercise group)

<table>
<thead>
<tr>
<th>Week #</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>8</th>
<th>10</th>
<th>12</th>
<th>14</th>
<th>16</th>
<th>18</th>
<th>21</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session with study physician or health care professional</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood pressure, weight and fasting glucose measure</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood glucose monitoring (finger prick testing)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Sessions with the dietitian</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Supervised exercise training*</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Home-based exercise**</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CGM sensor</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RESET ENG MUHC Information and Consent Form – version 2 – Feb 10, 2021
*= At least two supervised exercise sessions weekly from weeks 3 to 12.
** At least one unsupervised/home-based exercise session weekly from weeks 3 to 12 and three sessions weekly or equivalent from weeks 13 through 24
*** Each time you will wear it for two weeks (weeks 11 and 12; weeks 23 and 24)

**BENEFITS ASSOCIATED WITH THE RESEARCH STUDY**
You may or may not personally benefit from your participation in this research project. However, we hope that the study results will contribute to the advancement of scientific knowledge in the study field and help us find better treatments for patients.

**RISKS ASSOCIATED WITH THE RESEARCH STUDY**
A possible risk associated with this study is a breach of confidentiality or use of your personal information by a third party. To limit this risk, we will take the steps to protect your confidentiality described in the Confidentiality section, below.

1. **Risks associated with the research intervention (group 2 only)**

   **Physical activity and exercise:** With exercise, there are risks of injury to joints, bones, and muscles. If you wind up in the low energy diet and structured exercise group, during the supervised exercise sessions, you will receive advice on how to be safely active. You will participate in some exercises and may try out some gym equipment. Becoming physically active and exercising may sometimes lead to injury or bring to light health problems that were not obvious. You must inform study personnel and physician of any symptoms of shortness of breath, chest discomfort, or other pain. The study physician may have to further evaluate you. Our exercise specialists will ask you about any joint, muscle, or back problems that you may have. They will help you to tailor your exercise accordingly. It is your responsibility to follow their advice and inform them of any concerns you may have.

   **Low energy diet:** In past studies, the low energy diet has led to symptoms like constipation (18 to 47%), dizziness (4 to 32%), fatigue (11 to 25%), thirst (6%), and/or headache (8%). These tend to get better with fibre-based laxatives and time. We will be giving you a fibre-based laxative to use as needed. It is also important to drink as much water as needed when on the diet.

   **Stopping medications:** We will be stopping your diabetes and blood pressure medications at the beginning of the diet and exercise program. This will help to prevent drops in blood pressure and/or glucose that would happen if the low energy diet were combined with medications. Diet and exercise may lead to low blood sugar and low blood pressure, but this is unlikely when not taking medication. We will monitor your blood sugar and blood pressure levels with you during the study to see if at any point medications need to be restarted.

2. **Risks associated with research procedures.**

   **Blood tests:** The taking of blood samples may cause some discomfort, fainting, formation of a small blood clot or swelling of the vein on surrounding tissue, bleeding from the puncture site, and /or rarely an infection. There is a possibility that you may faint. However, precautions will be taken to ensure your safety should this occur.
**Treadmill testing:** As with any type of strenuous activity, there is a some risk of a serious event (e.g. heart attack, hypoglycemia) during the exercise tests that you will perform during the study. If at any time during the exercise tests you do not wish to continue for any reason, you may stop exercising. A health professional and physician will always be available during the treadmill test and emergency equipment will always be available in case of a serious event.

**Body composition DXA scans:** These procedures like X-rays use radiation energy to form images of your body and provide your doctor with other clinical information. Radiation can cause cell damage that may, after many years or decades, turn cancerous. We are all at risk of developing cancer during our lifetime. The normal risk is that this will happen to about 50% of people at some point in their life. Taking part in this study will add only a very small chance of this happening to you.

**MRI:** We will not perform an MRI on pregnant women. The magnetic field of the MRI may pose a risk to the developing fetus. The MRI table, on which you will lie on, will slide inside the MRI scanner. Less than 5% of people have anxiety or a feeling of claustrophobia because of the small space that they are in during the test. The scanner will emit radio frequencies that generate a loud noise, which will be lessened by the headphones we will give you to wear. During the exam, you can talk to the technologist or you can ask to stop the exam at any time. About 10% of people have headache or nausea related to the strong magnetic field of the MRI; these are usually mild and they go away. Some people may also experience a sensation of heat, tingling in the body, nausea and discomfort due to the loud noise.

**Questionnaires:** Some questions may upset some participants. For example, we will ask you about use of drugs and alcohol, past history of miscarriage, and symptoms of pain, anxiety, and depression. Please let us know if this upsets you and how we can help to support you. We may be able to help you find online resources or places to seek counselling, if necessary. We could also assist you in communicating any issues to your doctor.

**Glucose sensors:** There is a low risk of infection or bruising from the insertion of the sensor. These could last for a few days. The skin of some individuals is sensitive to the adhesive and can get red or itchy when the CGM is attached. There may be redness in the area where the tape was applied but this will usually disappear after a few days.

**RISKS ASSOCIATED WITH PREGNANCY**
The approach we are using has not been tested for safety in pregnant women. Therefore, it is important not to become pregnant during the study. In addition, if you are sexually active, and could become pregnant you must use a medically accepted contraceptive method throughout your participation in the study.

The medically accepted contraceptive methods are oral contraception, hormonal implants, hormonal patches, IUD, diaphragm and spermicide, cervical cap with spermicide, and condom with spermicide. The study doctor or the research team will discuss your contraceptive method with you to ensure that it is medically accepted.

If you suspect that you have become pregnant during your participation in the research study, you must inform the study staff immediately. The study doctor and staff will help arrange testing and
referral, as appropriate. If you are in Group 2, we will stop the low energy diet and supervised exercise program. For either Group 1 or Group 2, we will not do the other test procedures like MRI or treadmill testing.

VOLUNTARY PARTICIPATION AND THE RIGHT TO WITHDRAW
Your participation in this research project is voluntary. Therefore, you may refuse to participate. You may also withdraw from the project at any time, without giving any reason, by informing the study doctor or a member of the research team.

Your decision not to participate in the study, or to withdraw from it, will have no impact on the quality of care and services to which you are otherwise entitled, or on your relationship with the study doctor or clinical team.

The study doctor, the Research Ethics Board, the funding agency, or the Sponsor may put an end to your participation without your consent. This may happen if new findings or information indicate that participation is no longer in your interest, if you do not follow study instructions, or if there are administrative reasons to terminate the project.

If you withdraw or are withdrawn from the study, the information and biological material already collected for the study will be stored, analyzed and used to ensure the integrity of the study.

Any new findings that could influence your decision to stay in the research project will be shared with you as soon as possible.

CONFIDENTIALITY
During your participation in this study, the study doctor and their team will collect and record information about you in a study file. They will only collect information required to meet the scientific goals of the study.

The study file may include information from your medical chart, including your identity, concerning your past and present state of health, your lifestyle, as well as the results of the tests, exams, and procedures that you will undergo during this research project. Your research file could also contain other information, such as your name, sex, date of birth and ethnic origin.

All the information collected during the research project will remain strictly confidential to the extent provided by law. You will only be identified by a code number. The key to the code linking your name to your study file will be kept by the study doctor.

To ensure your safety, a copy of this information and consent form will be placed in your medical chart. As a result, any person or company to whom you give access to your medical chart will have access to this information.
We are conducting this study in collaboration with researchers in the United Kingdom (UK) and Canada. We may share the data collected with them, without any identifying information. This is so we can analyse the results from all the sites participating in this study. This will be done in such a way that you cannot be recognised from it. For example, shared data will not include names, addresses or dates of birth.

The study data will be stored for 25 years after completion of the trial.

The data may be published or shared during scientific meetings; however, precautions will be taken to ensure that it will not be possible to identify you.

You have the right to consult your study file in order to verify the information gathered, and to have it corrected if necessary.

However, in order to protect the scientific integrity of the research project, accessing certain information before the project is ended may require that you be withdrawn from the study.

For auditing purposes, the research study files which could include documents that may identify you may be examined by a person mandated by the study sponsor, the institution, or the Research Ethics Board. All these individuals and organizations adhere to policies on confidentiality.

INCIDENTAL FINDINGS
Material incidental findings are findings made in the course of the study that may have significant impacts on your current or future wellbeing or that of your family members. A material incidental finding concerning you in the course of this research will be communicated to you and to a health professional of your choice.

FUNDING OF THE RESEARCH PROJECT
The researcher and the institution have received funding from the Canadian Institutes of Health Research to conduct this research project.

COMPENSATION
You will receive an amount of $10 per visit to the Glen hospital (to cover parking and public transit costs) for each of the 5 study-related visits (see Table titled For everyone in the study (Group 1 and Group 2)).

For Group 2, parking costs at PERFORM will be paid directly by the study team to the PERFORM centre. The meal replacements and supervised exercise sessions (where applicable) will be offered to you for free for the duration of this research study.

SHOULD YOU SUFFER ANY HARM
Should you suffer harm of any kind due to a procedure related to the research study, you will receive the appropriate care and services required by your state of health.

By agreeing to participate in this research project, you are not waiving any of your legal rights nor discharging the study doctor, the sponsor or the institution, of their civil and professional responsibilities.
WHAT ABOUT COVID-19?
Your safety and that of our research team will be paramount. The study will comply with the latest recommendations and laws. This includes physical distancing and the use of personal protective equipment. If things change during the course of the study, we may need to change how we run the study. This may mean greater use of remote consultations and monitoring. The amount of exercise done at home may also need to be increased.

CLINICAL TRIAL REGISTRATION
A description of this clinical trial will be available on http://www.ClinicalTrials.gov. This Website will not include information that can identify you. At most, the Website will include a summary of the results. You can search this Website at any moment.

CONTACT INFORMATION
If you have questions or if you have a problem you think may be related to your participation in this research study, or if you would like to withdraw, you may communicate with:

- The Principal Investigator, Dr. Kaberi Dasgupta, at the McGill University Health Centre, at 514-934-1934, then 1 then ext. 44715; or
- The main research coordinator of the study, Ms. Debbie Chan, at 514-934-1934 then 1 then ext. 44835 or by email at debbie.chan@rimuhc.ca

For any question concerning your rights as a research participant taking part in this study, or if you have comments, or wish to file a complaint, you may communicate with McGill University Health Centre Ombudsman: 514-934-1934, then 1 then ext. 35655

OVERVIEW OF ETHICAL ASPECTS OF THE RESEARCH
The McGill University Health Centre Research Ethics Board reviewed this research and is responsible for monitoring the study.
SIGNATURES

Signature of the participant

I have reviewed the information and consent form. Both the research study and the information and consent form were explained to me. My questions were answered, and I was given sufficient time to make a decision. After reflection, I consent to participate in this research study in accordance with the conditions stated above.

I authorize the research study team to have access to my medical record for the purposes of this study.

I authorize the study doctor to inform my treating physician that I am taking part in this study.

I authorize the doctor in charge of this research study to communicate with me directly to ask if I am interested in participating in other research.

I understand that my doctor may be contacted to provide information about my health status to the research team for confirmation of eligibility.

Name and contact information of treating physician: ___________________________

Physician’s Address: ____________________________________________

Physician’s phone number: ______-______-_______

I understand that the study doctor will send my treating physician health information if it will be useful for my care.

____________________________________________________________________________________

Name of participant                                 Signature             Date (dd/mmm/yyyy)

Signature of the person obtaining consent

I have explained the research study and the terms of this information and consent form to the research participant, and I answered all his/her questions.

____________________________________________________________________________________

Name of the person obtaining consent                 Signature             Date (dd/mmm/yyyy)
## RESET 4 REMISSION Trial DMC Charter

1. **INTRODUCTION**

| Name (and sponsor’s ID) of trial plus ISRCTN and/or EUDRACT number | REMission of diabetes and improved diastolic function by combining Structured Exercise with meal replacement and food reintroduction: THE RESET FOR REMISSION TRIAL  
Sponsor: University of Leicester and McGill University  
Registration number: To be included |
|---|---|

### Objectives of trial, including interventions being investigated

<table>
<thead>
<tr>
<th>Primary objective</th>
</tr>
</thead>
<tbody>
<tr>
<td>The aim of this efficacy study is to investigate whether combining a low energy diet incorporating the phased use of meal replacement products, with structured exercise training leads to remission of T2DM in younger adults (18-40 years) over a 24-week period, in comparison with usual care. Remission is defined as an hba1c value less than 6.5% at 24 weeks and no antihyperglycemic medications during weeks 13 through 24 weeks of the 24 week study period.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Secondary objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Key secondary objectives will examine the effects of the combined intervention on cardiovascular and functional health, particularly MRI-assessed diastolic function and cardiometabolic risk factors such as lipid profile and peripheral blood pressure, along with cardiorespiratory fitness, physical function, lean mass and basal metabolic rate. We will also undertake a process evaluation, to ensure the findings from our research can be used to inform how the interventional components are refined and translated.</td>
</tr>
</tbody>
</table>

Figure 1 shows a flow chart of the trial design.

### Outline of scope of charter

The purpose of this document is to describe membership, terms of reference, roles, responsibilities, authority, decision-making and relationships of the independent Data Monitoring Committee (DMC) for the RESET 4 REMISSION trial. This will include the timing of meetings, methods of providing information to and from the DMC, frequency and format of meetings and relationships with other trial committees such as the Trial Steering Committee (TSC).

2. **ROLES AND RESPONSIBILITIES**

<table>
<thead>
<tr>
<th>A broad statement of the aims of the Data Monitoring Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>To safeguard the interests of trial participants, assess the safety of the interventions during the trial, and monitor the overall conduct of the clinical trial.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Terms of reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>The DMC should receive and review the progress and accruing data of this trial and provide advice on the conduct of the trial to the Trial Steering Committee.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Specific roles of DMC</th>
</tr>
</thead>
<tbody>
<tr>
<td>To undertake reviews of the trial’s progress, including updated figures on recruitment, data quality, and main outcomes and safety data, by:</td>
</tr>
</tbody>
</table>

- assess data completeness (and by so doing encourage collection of high-quality data)
- monitor recruitment figures and losses to follow-up
- monitor compliance with the protocol by participants and investigators
- monitor evidence for any potential treatment harm (e.g., Serious Adverse Events or deaths)
### RESERT 4 REMISSION Trial DMC Charter

- suggest additional data analyses as part of the review of the statistical analysis plan
- advise on protocol modifications suggested by investigators or sponsors (e.g., to inclusion criteria, trial endpoints, or sample size)
- monitor planned sample size assumptions
- monitor continuing appropriateness of participant information sheets
- monitor compliance with previous DMC recommendations
- assess the impact and relevance of external evidence as requested by the TSC, Trial Sponsors (University of Leicester and Research Institute of the McGill University Health Centre [RI-MUHC]) or Trial Funders (The UK Medical Research Council [MRC] and The Canadian Institutes of Health Research [CIHR])
- if funding is required above the level originally requested, the DMC may be asked by the Principal (Chief) Investigators, TSC, Trial Sponsors or Trial Funders to provide advice and, where appropriate, information on the data gathered to date in a way that will not compromise the trial.

### 3. BEFORE OR EARLY IN THE TRIAL

**Whether the DMC will have input into the protocol**

All potential DMC members should read the protocol/outline before agreeing to join the committee. Before recruitment begins the trial will have undergone review by the funders (UK Medical Research Council and Canadian Institutes of Health Research), the sponsors (University of Leicester and RI-MUHC), and other relevant trial committees including that of research ethics committees. Therefore, if a potential DMC member has major reservations about the trial (e.g., the protocol or the logistics) they should report these to the Chief Investigators and may decide not to accept their invitation to join. DMC members should be constructively critical of the ongoing trial, but also supportive of aims and methods of the trial.

**Whether the DMC will meet before the start of the trial**

It is recommended that, if possible, the DMC meets before the start or early in the course of the trial, to discuss the protocol, the trial, any analysis plan, future meetings, and to have the opportunity to clarify any aspects with the principal investigators.

**Any issues specific to the disease under study**

The study population comprises younger (18 – 40 years) adults with type 2 diabetes. These individuals are at risk of developing chronic (e.g., cardiovascular disease) or acute (e.g. hyperglycaemia) complications related to their diabetes. The protocol lists the possible adverse events of study interventions within this population.

**Any specific regulatory issues**

None

**Any other issues specific to the treatment under study**

None

**Whether members of the DMC will have a contract**

DMC members will not be asked to formally sign a contract but should formally register their agreement to join the group by confirming; (1) that they agree to be a member of the DMC and (2) that they agree with the contents of this Charter. Any potential competing interests, real or potential, should be declared at the same time using a short competing interest form (displayed in Annex 1), which should be completed and returned by the DMC members to the trial coordinating centre. DMC members should sign and maintain this log of potential competing interests.
RESET 4 REMISSION Trial DMC Charter

4. COMPOSITION

Membership and size of the DMC

Members of the DMC (including the DMC Chair) should be independent of the trial. The definition of independent is as follows:

- Not part of the same institution as any of the applicants or members of the project team
- Not part of the same institution that is acting as a recruitment or investigative centre
- Not related to any of the applicants or members of the project team
- For the chair only – not an applicant on a rival proposal

The membership will consist of three individuals including two clinicians experienced in the clinical area and one statistician. Members have been chosen because they are experienced in trials and/or the disease area.

The members of the DMC for the RESET 4 REMISSION Trial are:

1. Dr Janusz Kaczorowski (Chair), Professor of Family and Emergency Medicine, University of Montreal
2. Mr Stephen Sharp (Statistician), MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine
3. Dr Andrew Farmer (Clinical Representative), Professor of General Practice, Nuffield Department of Primary Care Health Sciences, University of Oxford

The Chair, how they are chosen and the Chair’s role. (Likewise, if relevant, the vice-Chairman)

The chair is Dr. Janusz Kaczorowski (Professor and Research Director in the Department of Family and Emergency Medicine – University of Montreal) who is serving on the DMC. The Chair is expected to facilitate and summarise discussions. There is no vice-Chair.

The responsibilities of the DMC statistician

The DMC membership includes a statistician (Mr Stephen Sharp) whose role it is to provide independent statistical expertise and to further guide the other DMC members through the report. The DMC statistician is not expected to prepare the DMC report.

The responsibilities of the trial statistician

The trial statistician (Dr Elham Rahme) will produce (or oversee the production of) the report to the DMC and will participate in DMC meetings, guide the DMC through the report, may participate in DMC discussions and, on some occasions, taking notes.

The responsibilities of the trial office team

The trial management team (e.g., Trial Managers/Coordinators) will input to the production of the DMC report.

The responsibilities of the PI and other members of the Trial Management Group (TMG)

The PI’s (Professor Thomas Yates and Professor Kaberi Dasgupta), may be asked, and should be available, to attend open sessions of the DMC meeting. The other TMG members will not usually be expected to attend but can attend open sessions when necessary (see Section 6 regarding ‘Organisation of DMC Meetings’ below).

5. RELATIONSHIPS

Relationships with Principal Investigators, other trial committees (eg Trial Steering Committee (TSC) or Executive Committee), sponsor and regulatory bodies

The DMC are advisory to the Trial Steering Committee (which includes the PI’s). The TSC is the executive body for the trial.

Clarification of whether the DMC is

The DMC is advisory to the Trial Steering Committee. The TSC is the executive body for the trial.
# RESET 4 REMISSION Trial DMC Charter

<table>
<thead>
<tr>
<th>advisory (make recommendations) or executive (make decisions)</th>
<th>body for the trial.</th>
</tr>
</thead>
</table>

## Payments to DMC members
Members will be reimbursed for reasonable travel costs and other expenses incurred, but it is anticipated that the meetings will be virtual. No other payments or rewards would be given to professional members.

## The need for DMC members to disclose information about any competing interests
Competing interests should be disclosed. These are not restricted to financial matters— involvement in other trials or intellectual investment could be relevant. Although members may well be able to act objectively despite such connections, complete disclosure enhances credibility (See Annex 1 towards end of DMC Charter document).

DMC members should not use interim results to inform trading in pharmaceutical shares and careful consideration should be given to trading in stock of companies with competing products. Changes in declarations of real or potential competing interests should be documented within the minutes at the start of each meeting.

---

## 6. ORGANISATION OF DMC MEETINGS

### Expected frequency of DMC meetings
The DMC should meet 6-monthly to annually, or more often as appropriate either in person or via teleconference. Some trial issues may need to be dealt with between meetings, by phone or by email. DMC members should be prepared for such instances. Additional *ad hoc* meetings will be scheduled with the occurrence of any severe adverse event including death, hospitalization, or emergency room consultation. During these meetings, reports from the PIs will be reviewed, regarding the SAE in question and the relatedness to trial procedures. The DSC will then determine whether further adjudication is warranted and what type of expertise is required; in these instances, two physicians from the relevant research site will be invited to review the event and medical records and comment on relatedness. If there is a difference of opinion, a third physician will be invited to review. The physicians may be trial investigators but they must be blinded to the trial arm and cannot have interacted with the participant during the course of the trial.

Regularly-scheduled meetings should be timed approximately 1 month prior to TSC meetings, so that reports can be fed to the TSC accordingly.

### Whether meetings will be face-to-face or by teleconference
Given the international context, the default will be to hold meetings over videoconference. Effort will be made to ensure that all members can attend.

### How DMC meetings will be organised, especially regarding open and closed sessions, including who will be present in each session
Upon request by the DMC, the format will be an open session throughout where all parts of the report are discussed and there is DMC discussion. The DMC members can ask for a closed session at any point in the DMC (± trial statistician at discretion of the DMC chair).

---

## 7. TRIAL DOCUMENTATION AND PROCEDURES TO ENSURE CONFIDENTIALITY AND PROPER COMMUNICATION

### Intended content of material to be available in sessions
Accumulating information relating to recruitment and retention, and data quality (e.g., data return rates, treatment compliance) will be presented by intervention arm. No formal interim analyses are planned. A log of adverse events will be presented at each meeting and discussed. Outcome data will not be presented. However, if the DMC has any concerns related to safety, pooled outcome data may be presented, and, in discussion with the TSC, unblinding may be permitted.
# RESET 4 REMISSION Trial DMC Charter

## Will the DMC be blinded to the treatment allocation

The DMC will not be blinded to recruitment data by treatment arm. No formal interim analyses are planned. The DMC will remain blinded unless safety concerns arise. However, primary and secondary outcome data will be based on pooled data, and the DMC will remain blinded unless unblinding is requested related to concerns about safety.

## Who will see the accumulating data

There are no planned interim analyses. The accumulating data presented to the DMC by intervention arm will relate only to attrition and to safety. If the DMC deems that safety concerns then unblinding may occur as indicated above. Interim data and analyses by intervention/control group (and the deliberations of the DMC) should be available only to those present in the DMC meetings when the discussions occurred: i.e., only members of the DMC, the trial statistician and other members of the trial team, as agreed by the DMC. DMC members must not share confidential information with people outside the DMC.

## Who will be responsible for identifying and circulating external evidence (e.g., from other trials/systematic reviews)

Identification and circulation of external evidence (e.g., from other trials/systematic reviews) is not the responsibility of the DMC members. It is the responsibility of the TMG (Trial Management Group). However, the DMC should continue to be made aware of other data that may impact the trial.

## To whom the DMC will communicate the decisions/recommendations that are reached

The DMC will report its recommendations via the chair in writing to the Trial Steering Committee (TSC, please see Annex 2). This should be sent in time for consideration at a TSC meeting. If the trial is to continue largely unchanged then it is often useful for the report from the DMC to include a summary paragraph suitable for trial promotion purposes.

## Whether reports to the DMC be available before the meeting or only at/during the meeting

It is planned that the DMC will receive data monitoring reports (i.e., recruitment, attrition, numbers in various study stages, numbers completed) from the TMG at least 2 weeks before scheduled meetings.

## What will happen to the confidential papers after the meeting

The DMC members should store the papers safely after each meeting so they may check the next report against them. After the trial is reported, the DMC members should destroy all interim reports.

## 8. DECISION MAKING

### What decisions/recommendations will be open to the DMC

Possible recommendations to the TSC could include:

- No action needed; trial continues as planned
- Early stopping due, for example, to clear harm of a treatment or external evidence (this should generally involve a recommendation from the DMC to unblind the TSC to this data)
- Modifying target recruitment, or pre-analysis follow-up, based on any change to the assumptions underlying the original trial sample size calculation (but not on any emerging differences)
- Sanctioning and/or proposing protocol changes

Ultimately, decisions will be made by the TSC, as the DMC’s role is advisory.

### The role of formal statistical methods, specifically which methods will be used and whether they will be used as guidelines or rules

The DMC and TSC will be asked to comment on and approve the trial statistical analysis plan (SAP) before database lock.

### How decisions or recommendations will be reached within the DMC

Every effort should be made to achieve consensus. The role of the DMC Chair is to summarise discussions and encourage consensus; therefore, it is usually best for the Chair to give their own opinion last.
### RESET 4 REMISSION Trial DMC Charter

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>It is important that the implications (e.g., ethical, statistical, practical, financial) for the trial be considered before any decision is made. Only appointed members will be entitled to vote and the chair will have a casting vote.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>When the DMC is quorate for decision-making</strong></td>
<td>Effort should be made for all DMC members to attend. The TMG will try to ensure that a date is chosen to enable this. Members who cannot attend in person should be encouraged to attend by teleconference. If, at short notice, any DMC members cannot attend at all then the DMC may still meet if at least two members will be present (including the Chair). If the DMC is considering recommending major action after such a meeting, the DMC Chair should talk with the absent members as soon after the meeting as possible to check whether they agree with such action. If they do not, a further teleconference should be arranged with the full DMC.</td>
</tr>
<tr>
<td><strong>Can DMC members who cannot attend the meeting input</strong></td>
<td>If the report is circulated before the meeting, DMC members who will not be able to attend the meeting may pass comments to the DMC Chair for consideration during the discussions.</td>
</tr>
<tr>
<td><strong>What happens to members who do not attend meetings</strong></td>
<td>If a member does not attend a meeting, it should be ensured that the member is available for the next meeting. If a member does not attend a second meeting, they should be asked if they wish to remain part of the DMC. If a member does not attend a third meeting, they should be replaced.</td>
</tr>
<tr>
<td><strong>Whether different weight will be given to different endpoints (e.g., safety/efficacy)</strong></td>
<td>This study is unlikely to result in safety issues, therefore greater weight should be given to efficacy considerations.</td>
</tr>
<tr>
<td><strong>Any specific issues relating to the trial design that might influence the proceedings, eg cluster trials, equivalence trials, multi-arm trials</strong></td>
<td>This is a 2-arm trial, occurring in the UK (Leicester) and Canada (Montreal, Edmonton). It is likely that the TSC/ DMC will need to consider issues specific to UK or Canadian sites in equivalent trials.</td>
</tr>
<tr>
<td><strong>9. REPORTING</strong></td>
<td>The DMC Chair should report in writing to the Chair of the Trial Steering Committee, usually within 3 weeks after the meeting. Unless the DMC is recommending that the trial protocol be changed in some way, the letter to the TSC should not reveal any confidential information. An example of a letter from a DMC to the TSC recommending no action is presented in Annex 2. Additionally, the letter should be copied to the PIs, trial statistician and trial managers.</td>
</tr>
<tr>
<td><strong>Minutes including key points and actions will be made by a member of the trials’ office team (to be decided prior to each meeting). This will include details of whether any competing interests have arisen/changed for any attendees since the previous meeting. The draft minutes will be initially circulated for comment to all DMC members who were present at the meeting. The DMC Chair will then sign off the final version of minutes. The final signed version will then be sent to all members, the sponsor, the funder and stored in the trial master file.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>What will be done if there is disagreement between the DMC and the body to which it reports</strong></td>
<td>The TSC has ultimate responsibility for the trial and assumes primacy. However, the TSC should report to the DMC regarding how they have acted upon the DMC’s recommendations. If the DMC has serious problems or concerns with the TSC decision, a joint meeting of the TSC and DMC should be held. The information to be shown would depend upon the action proposed and each committee’s concerns. The meeting would be Chaired by...</td>
</tr>
</tbody>
</table>
## RESET 4 REMISSION Trial DMC Charter

<table>
<thead>
<tr>
<th>10. AFTER THE TRIAL</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Publication of results</strong></td>
<td>The PIs have responsibility that trial results will be published in a correct and timely manner. The TSC is the committee that should oversee this process.</td>
</tr>
<tr>
<td><strong>The information about the DMC that will be included in published trial reports</strong></td>
<td>DMC members will be named and their affiliations listed in the main report, unless they explicitly request otherwise.</td>
</tr>
<tr>
<td><strong>Whether the DMC will have the opportunity to approve publications, especially with respect to reporting of any DMC recommendation regarding termination of a trial</strong></td>
<td>The DMC members should be given at least 2 weeks to read and comment on any draft publications that report the primary outcome measure and/or details of the DMC. This may be done simultaneously to other groups reviewing the draft manuscript (e.g. Trial Steering Committee, trial investigators).</td>
</tr>
<tr>
<td><strong>Any constraints on DMC members divulging information about their deliberations after the trial has been published</strong></td>
<td>The DMC should not discuss confidential issues from their involvement in the trial until 12 months after the primary trial results have been published, unless permission is agreed with the TSC. The TSC will also decide when it is appropriate for TMG and DMC members to trade in related stocks.</td>
</tr>
</tbody>
</table>

a senior member of the trials office staff or an external expert who is not directly involved with the trial.
DMC Charter for R4R
Date: 15/01/2021
Version: 1.0

Pre-screening

Consent and baseline assessments (VISITS 0, 1 & 2)*
(UK n = 40, Canada n = 40)

Randomisation

Standard care UK n = 20, Canada n = 20

Low energy diet incorporating phased meal replacement plan combined with exercise training UK n=20, Canada n = 20

Dietary Support Weeks 1 through 12
Initial meeting with study dietitian for intervention planning in week 0 with core follow-on support provided in weeks 1, 2, 4, 8

Exercise Support Weeks 3 through 12
Structured exercise sessions three times per week, at least two of which directly supervised

Clinical review (Baseline, week 1, 2, 4, 8)
*Blood pressure, glucose and weight
*Antihyperglycemics and antihypertensives withdrawn at week 0; reintroduced/rew withdrawn as clinically needed

Week 12 intermediate outcome assessments (VISIT 3)*
*Baseline, week 12 and week 24 visits include: HbA1c, accelerometer monitoring, resting energy expenditure, DXA scan, weight, neck and waist circumference, urine sample, blood pressure, fasting glucose, lipids, BMI, maximal exercise test, short physical performance battery, food diary, questionnaires; only baseline and final assessments include MRI

Dietary Support weeks 12-24
Core dietary support sessions Week 12, 14, 16, 18 & 21

Exercise Support weeks 12-24
Core exercise support sessions Week 12, 14, 16, 18 & 21

Clinical review weeks 12-24
Week 12, 14, 18

Tapering of meal replacement plan and ‘relapse management’
Weeks 13-24

Tapered exercise supervision and ‘relapse management’
Weeks 13-24

Week 24 final outcome assessments (VISITS 4 & 5) *
Exit consultation with dietitian, exercise specialist, study physician(s)

Control group offered the 12 week low energy diet and meal replacement plan, followed by a 4-week food reintroduction period

Process evaluation with intervention

Consent and baseline assessments (VISITS 0, 1 & 2)*
(UK n = 40, Canada n = 40)

Low energy diet incorporating phased meal replacement plan combined with exercise training UK n=20, Canada n = 20

Dietary Support Weeks 1 through 12
Initial meeting with study dietitian for intervention planning in week 0 with core follow-on support provided in weeks 1, 2, 4, 8

Exercise Support Weeks 3 through 12
Structured exercise sessions three times per week, at least two of which directly supervised

Clinical review (Baseline, week 1, 2, 4, 8)
*Blood pressure, glucose and weight
*Antihyperglycemics and antihypertensives withdrawn at week 0; reintroduced/rew withdrawn as clinically needed

Week 12 intermediate outcome assessments (VISIT 3)*
*Baseline, week 12 and week 24 visits include: HbA1c, accelerometer monitoring, resting energy expenditure, DXA scan, weight, neck and waist circumference, urine sample, blood pressure, fasting glucose, lipids, BMI, maximal exercise test, short physical performance battery, food diary, questionnaires; only baseline and final assessments include MRI

Dietary Support weeks 12-24
Core dietary support sessions Week 12, 14, 16, 18 & 21

Exercise Support weeks 12-24
Core exercise support sessions Week 12, 14, 16, 18 & 21

Clinical review weeks 12-24
Week 12, 14, 18

Tapering of meal replacement plan and ‘relapse management’
Weeks 13-24

Tapered exercise supervision and ‘relapse management’
Weeks 13-24

Week 24 final outcome assessments (VISITS 4 & 5) *
Exit consultation with dietitian, exercise specialist, study physician(s)
Annex 1: Suggested competing interests form

RESET 4 REMISSION Trial (Sponsor: University of Leicester and McGill University): Agreement to join the Data Monitoring Committee as an independent member and disclosure of potential competing interests

Please complete the following document and return to the Trials Office

(Please initial box to agree)

☐ I have read and understood the DMC Charter version 1.0, dated 15th March 2021

☐ I agree to join the Data Monitoring Committee for this trial as an independent member

☐ I agree to treat all sensitive trial data and discussions confidentially

The avoidance of any perception that independent members of a DMC may be biased in some fashion is important for the credibility of the decisions made by the DMC and for the integrity of the trial.

Potential competing interests should be disclosed via the trials office. In many cases simple disclosure up front should be sufficient. Otherwise, the (potential) independent DMC member should remove the conflict or stop participating in the DMC. Table 1 lists potential competing interests.

☐ No, I have no potential competing interests to declare

☐ Yes, I have potential competing interests to declare (please detail below)

Please provide details of any potential competing interests:

________________________________________________________________________

________________________________________________________________________

________________________________________________________________________

Name: ________________________

Signed: ________________________ Date: ______________

Table 1: Potential competing interests for independent members

- Stock ownership in any commercial companies involved
- Stock transaction in any commercial company involved (if previously holding stock)
- Consulting arrangements with the Sponsor/Funder
- Ongoing advisory role to a company providing drugs to the trial
- Frequent speaking engagements on behalf of the intervention
- Career tied up in a product or technique assessed by trial
- Hands-on participation in the trial
- Involvement in the running of the trial
- Emotional involvement in the trial
- Intellectual conflict e.g. strong prior belief in the trial’s experimental arm
- Involvement in regulatory issues relevant to the trial procedures
- Investment (financial or intellectual) or career tied up in competing products
- Involvement in the writing up of the main trial results in the form of authorship
Annex 2: Suggested report from DMC to TSC where no recommendations are being made

[Insert date]

To: Professor XX (Chair of Trial Steering Committee)

Dear Professor XX,

The Data Monitoring Committee (DMC) for the RESET 4 REMISSION Trial met on [meeting date] to review its progress and interim accumulating data. [List members] attended the meeting and reviewed the report.

We congratulate the trial organisers and collaborators on the progress and conduct of the trial and the presentation of the data. The trial question remains important and, on the basis of the data reviewed at this stage, we recommend continuation of the trial according to the current version of the protocol [specify protocol version number and date] with no changes.

We shall next review the progress and data [provide approximate timing]

Yours sincerely,

Professor XX
Chair of Data Monitoring Committee

On behalf of the DMC (all members listed below)

DMC members:
(1) xx
(2) xx
(3) xx
# RESET FOR REMISSION TRIAL TSC CHARTER

## 1. INTRODUCTION

Name (and sponsor’s ID) of trial plus ISRCTN and/or EUDRACT number

REmission of diabetes and improved diastolic function by combining Structured Exercise with meal replacement and food reintroduction: THE RESET FOR REMISSION TRIAL

Sponsor: University of Leicester and McGill University

Registration number: To be included

Objectives of trial, including interventions being investigated

### Primary objective

The aim of this efficacy study is to investigate whether combining a low energy diet incorporating the phased use of meal replacement products, with structured exercise training leads to remission of T2DM in younger adults (18-40 years) over a 24 week period. Remission is defined as an HbA1c value less than 6.5% without antihyperglycemic medications during weeks 13 through 24 weeks of the 24 week study period.

### Secondary objectives

Key secondary objectives will examine the effects of the combined intervention on cardiovascular and functional health, particularly MRI-assessed diastolic function and cardiometabolic risk factors such as lipid profile and peripheral blood pressure, along with cardiorespiratory fitness, physical function, lean mass and basal metabolic rate. We will also undertake a process evaluation, to ensure the findings from our research can be used to inform how the interventional components are refined and translated.

Figure 1 shows a flow chart of the trial design.

Outline of scope of charter

The purpose of this document is to describe the membership, terms of reference, roles, responsibilities, authority, decision-making and relationships of the Trial Steering Committee (TSC) for this trial, including the timing of meetings, methods of providing information to and from the TSC, frequency and format of meetings and relationships with other trial committees.

## 2. ROLES AND RESPONSIBILITIES

A broad statement of the aims of the TSC

To act as the oversight body for the Reset For Remission Trial on behalf of the Sponsor/Funder.

Terms of reference

The role of the TSC is to provide oversight for the trial. It should also provide advice, through its Chair, to the CIs (PIs), the Sponsors (University of Leicester and Research Institute of the McGill University Health Centre), the Funders (The Canadian Institutes of Health Research [CIHR] and the UK Medical Research Council [MRC]), and the Host Institution on all appropriate aspects of the trial but with a particular focus on:

- Progress of the trial, adherence to the protocol, participant safety and the consideration of new information of relevance to the research question.
The rights, safety and well-being of the trial participants are the most important considerations and should prevail over the interests of science and society.

To ensure appropriate ethical and other approvals are obtained in line with the project plan

To review proposals for substantial protocol amendments and provide advice to the sponsor and funder regarding approvals of such amendments, where appropriate.

To provide advice to the investigators on all aspects of the trial.

Specific roles of TSC

The specific roles of the TSC as a body will be to:

- provide expert oversight of the trial
- make decisions as to the future continuation (or otherwise) of the trial
- monitor recruitment rates and encourage the Trial Management Group (TMG) to develop strategies to deal with any recruitment problems
- review regular reports of the trial from the trials coordinators (sent on behalf of the TMG)
- receive letters of feedback from the DMC (Data Monitoring Committee) and consider their recommendations
- assess the impact and relevance of any accumulating external evidence (provided by the TMG)
- monitor follow-up rates and review strategies from TMG to deal with problems
- ensure sites that are complying with the protocol
- approve major amendments to the protocol
- approve any proposals by the TMG concerning any change to the design of the trial, including additional sub studies
- oversee the timely reporting of trial results
- comment on the statistical analysis plan
- comment on the publication policy
- comment on the main trial manuscript
- approve and comment on any abstracts and presentations of any results during the running of the trial
- approve external or early internal requests for release of data or subsets of data or samples including clinical data and stored biological samples

It is the responsibility of individual members of the TSC to maintain confidentiality of all trial information that is not already in the public domain.

3. BEFORE OR EARLY IN THE TRIAL

TSC input into the protocol

All potential independent TSC members should have opportunity to comment on the protocol as early as possible. If a potential independent TSC member has major reservations about the trial (e.g., the protocol, the logistics, ethical concerns) they should report these to the TMG and may decide not to accept the invitation to join. TSC members should be constructively critical of the protocol, but also supportive of aims and methods of the trial.

Any issues specific to the disease under study

The study population comprises younger (18 – 40 years) adults with type 2 diabetes. These individuals are at risk of developing chronic (e.g. cardiovascular disease) or acute (e.g. hyperglycaemia) complications related
## RESET FOR REMISSION TRIAL TSC CHARTER

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3. ADVERSE EVENTS</strong></td>
<td>The protocol lists the possible adverse events of study interventions within this population</td>
</tr>
<tr>
<td>Any specific regulatory issues</td>
<td>None</td>
</tr>
<tr>
<td>Any other issues specific to the treatment under study</td>
<td>None</td>
</tr>
<tr>
<td>Whether members of the TSC will have a contract</td>
<td>TSC members will not be asked to formally sign a contract but should formally register their agreement to join the group by confirming (1) that they agree to be a member of the TSC and (2) that they agree with the contents of this Charter. Any potential competing interests should be declared at the same time. Members should complete and return the form in Annex 1 or 2 by email. Any observers (attendees who are not members) will sign a confidentiality agreement on the first occasion they attend a meeting (Annex 3).</td>
</tr>
</tbody>
</table>

### 4. COMPOSITION

<table>
<thead>
<tr>
<th>Membership and size of the TSC</th>
<th>Apart from the studies PIs (Dasgupta, Yates), the members of the TSC, including the Chair, should be independent of the trial. Non-independent members will also be part of the TSC. The definition of independent is as follows:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Not part of the same institution as any of the applicants or members of the project team</td>
</tr>
<tr>
<td></td>
<td>• Not part of the same institution that is acting as a recruitment or investigative centre</td>
</tr>
<tr>
<td></td>
<td>• Not related to any of the applicants or members of the project team</td>
</tr>
<tr>
<td></td>
<td>• For the chair only – not an applicant on a rival proposal</td>
</tr>
</tbody>
</table>

The membership will consist of three individuals including two clinicians experienced in the clinical area and one statistician. Members have been chosen because they are experienced in trials and/or the disease area. The members of the TSC for this trial are:

1. **Professor Jason Gill** (Chair), Professor of Cardiometabolic Health, University of Glasgow
2. **Dr Alice Cheng** (Clinical representative), Physician and Associate Professor of Medicine, University of Toronto
3. **Dr Elham Rahme** (Trial statistician)
4. **Professor Kaberi Dasgupta** and **Prof Tom Yates**, PIs

Only appointed members will be entitled to vote. The PIs or their delegates are allocated one vote in total.

| The Chair | The chair is Prof Jason Gill (Professor of Cardiometabolic Health at the University of Glasgow) who is serving on the TSC. The Chair is expected to facilitate and summarise discussions. There is no vice-Chair. |
RESET FOR REMISSION TRIAL TSC CHARTER

The Chair is directly answerable to the Sponsor and Funders. The Chair’s responsibilities include:

- Arranging, along with the PIs and trials office, an inaugural meeting to set up a schedule of meetings to align with the project plan
- Being familiar with relevant guidance documents and with the role of the DMC
- Providing an independent, experienced opinion if conflicts arise between the needs of the research team, the funder, the sponsor, the participating organisations and/or any other agencies
- Leading the TSC to provide regular, impartial oversight of the trial, especially to identify and pre-empt problems
- Ensuring that changes to the protocol are debated and endorsed by the TSC. Letters of endorsement should be made available to the project team when requesting approval from the funder and sponsor for matters such as substantive changes to protocol
- Being available to provide independent advice as required, not just when TSC meetings are scheduled
- Commenting on any extension requests and, where appropriate, providing a letter of recommendation to accompany such a request
- Commenting in detail, when appropriate, regarding the continuation or termination of the project

The Chair is directly answerable to the Sponsor and Funders. The Chair’s responsibilities include:

- Arranging, along with the PIs and trials office, an inaugural meeting to set up a schedule of meetings to align with the project plan
- Being familiar with relevant guidance documents and with the role of the DMC
- Providing an independent, experienced opinion if conflicts arise between the needs of the research team, the funder, the sponsor, the participating organisations and/or any other agencies
- Leading the TSC to provide regular, impartial oversight of the trial, especially to identify and pre-empt problems
- Ensuring that changes to the protocol are debated and endorsed by the TSC. Letters of endorsement should be made available to the project team when requesting approval from the funder and sponsor for matters such as substantive changes to protocol
- Being available to provide independent advice as required, not just when TSC meetings are scheduled
- Commenting on any extension requests and, where appropriate, providing a letter of recommendation to accompany such a request
- Commenting in detail, when appropriate, regarding the continuation or termination of the project

The responsibilities of the trial office team

The trials office team will produce a short report on the trial before each meeting of the TSC. A template for the report will be followed.

The responsibilities of the PI and other members of the Trial Management Group (TMG)

The PI is an important member of the TSC and no major decisions should be made without their involvement.

The responsibilities of the observers

Additional observers may be in attendance through (parts of) the TSC meetings in order to provide input on behalf of the trials office, the trial’s Sponsor/Funder or to provide specific relevant expertise.

5. RELATIONSHIPS

Advisory and executive bodies

The TSC is the oversight body (see Roles and responsibilities above). All substantial issues regarding the trial must go to the TSC for consideration. The DMC is advisory to the TSC.

Payments to TSC members

Members will be reimbursed for reasonable travel costs and other expenses incurred. No other payments or rewards would be given to professional members.

The need for TSC members to disclose information about any competing interests

Competing interests should be disclosed. These are not restricted to financial matters – involvement in other trials or intellectual investment could be relevant. Although members may well be able to act objectively despite such connections, complete disclosure enhances credibility (See Annex 1).

TSC members should not use interim results to inform trading in pharmaceutical shares, and careful consideration should be given to trading...
# RESET FOR REMISSION TRIAL TSC CHARTER

## 6. ORGANISATION OF TSC MEETINGS

| **Expected frequency of TSC meetings** | The TSC will meet at 6-monthly to annually depending on need as determined by the Chair, either in person or via teleconference. At the request of the TSC, interim meetings, in person or by teleconference, will be organised. Some trial issues may need to be dealt with between meetings, by phone or by email. TSC members should be prepared for such instances. It is expected that the TSC will meet approximately one month after the DMC. |
| **Attendance of TSC members at meetings** | Given the international context, the default will be to hold meetings over videoconference. Effort will be made to ensure that all members can attend. At least one PI must attend all meeting. If, at short notice, any TSC members cannot attend then the TSC may still meet if at least two independent members will be present, along with a PI. There may be occasions when the Trial Sponsors or Funders will wish to organise and administer these meetings. |
| **How TSC meetings will be organised, especially regarding open and closed sessions, including who will be present in each session** | Presence will be usually limited to the TSC members, and observers from the TMG. Other attendees may be invited for all or part of the meeting by the TSC Chair. Meeting will be organised by Trials office, in coordination with the PIs and Chair. |
| **Input from TSC members who cannot attend the meeting** | If the report is circulated before the meeting, TSC members who will not be able to attend the meeting may pass comments to the TSC Chair or trials office contact for consideration during the discussions. |
| **What happens to independent members who do not attend meetings** | If an independent member does not attend a meeting or provide comments when requested between meetings, it should be ensured that the independent member is available for the next meeting. If an independent member does not attend the next meeting or provide comments when next requested, they should be asked if they wish to remain part of the TSC. If an independent member does not attend a third meeting, strong consideration should be given to replacing this member. |

## 7. TRIAL DOCUMENTATION AND PROCEDURES TO ENSURE CONFIDENTIALITY AND PROPER COMMUNICATION

| **Intended content of material to be considered during meetings** | A short report will be prepared by the trial coordinators following a standard template. This will report on accrual and any matters affecting the trial. Additionally, the material may include a report from the DMC, requests from the TMG or draft publications. No trial outcome measure data will be presented by arm unless explicitly authorised by the DMC (e.g., safety outcomes). If specifically requested by the TSC, accrual, compliance with follow-up and adherence to treatment may be presented by site. |
| **Whether reports to the TSC will be available before the meeting or only at/during the meeting** | It is planned that the TSC will receive the report at least 1 week and preferably at least 2 weeks before any meetings. |
| **Responsibility for identifying and** | Identification and circulation of external evidence (e.g., from other trials/ |
# RESTART FOR REMISSION TRIAL TSC CHARTER

### circulating external evidence (e.g. from other trials/systematic reviews)

systematic reviews) is not the responsibility of the TSC members; it is a responsibility of the TMG. However, the TSC should continue to be made aware of other data that may impact on a trial.

### What will happen to the papers after the meeting

TSC members will be expected to securely store copies of the reports to and from the TSC, agenda and minutes, as well as copies of communications between meetings so they may check the next report against them. All documentation should be considered confidential. After the trial is reported, the TSC members should destroy all interim reports. The trials office will keep a central record of all minutes, reports and correspondence by the TSC.

## 8. DECISION MAKING

### What decisions will be open to the TSC

Based on recommendations from the DMC, possible decisions include:-

- No action needed; trial continues as planned.
- Early stopping due, for example, to clear harm of a treatment or external evidence (this should generally involve a recommendation from the DMC to unblind the TSC to this data).
- Modifying target recruitment, or pre-analysis follow-up, based on any change to the assumptions underlying the original trial sample size calculation (but not on any emerging differences).
- Sanctioning and/or proposing protocol changes.

Based on other factors, possible decisions include the decisions above and:

- Censuring centres for poor data quality.
- Approving proposed protocol amendments or new trial sub-studies.
- Approving requests for early release of (subsets of) data.
- Approving presentation of results during the trial or soon after closure.
- Approval of new centres or strategies to improve recruitment or follow-up.

### The role of formal statistical methods

The TSC will be asked to comment on and approve trial statistical analysis plan (SAP) before database lock.

### How decisions or recommendations will be reached within the TSC

Every effort should be made to achieve consensus. The role of the Chair is to summarise discussions and encourage consensus; therefore, it is usually best for the Chair to give their own opinion last.

It is important that the implications (e.g., ethical, statistical, practical, financial) for the trial be considered before any decision is made.

### When the TSC is quorate for decision-making

At least two independent members of the TSC should be present including the Chair, along with at least one PI.

### Any specific issues relating to the trial design that might influence the proceedings, e.g. cluster trials, equivalence trials, multi-arm trials

This is a 2-arm trial, occurring in the UK (Leicester) and Canada (Montreal, Edmonton). It is likely that the TSC will need to consider issues specific to UK or Canadian sites.

### 9. REPORTING

To whom will the TSC report their recommendations/decisions, and in what form?

Reports will be returned to the TMG who will be responsible for implementing any actions resulting. The TSC may also provide feedback to

---

# RESET FOR REMISSION TRIAL TSC CHARTER

<table>
<thead>
<tr>
<th><strong>what form</strong></th>
<th>the DMC and, where appropriate, to the Sponsors or Funders.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Whether minutes of the meeting be made and, if so, by whom and where they will be kept</strong></td>
<td>Notes of key points and actions will be made by a member of the trial management team. This will include details of whether potential competing interests have changed for any attendees since the previous meeting. The draft minutes will be initially circulated for comment to those TSC members who were present at the meeting. The TSC Chair will sign off the final version of minutes or notes. The final version will then be sent to all members, the sponsor, the funder and the trial master file.</td>
</tr>
<tr>
<td><strong>What will be done if there is disagreement between the TSC and other trial committees</strong></td>
<td>The TSC is the oversight body for the trial. However, the TSC should have good reason before deciding not to accept requests from the TMG and recommendations from the DMC. If there are serious problems or concerns with the TSC decision following a DMC recommendation, a joint meeting of the TSC and DMC should be held. The information to be shown would depend upon the action proposed and each committee’s concerns. The meeting would be Chaired by a senior member of the trial management staff or an external expert who is not directly involved with the trial.</td>
</tr>
</tbody>
</table>

## 10. AFTER THE TRIAL

| **Publication of results** | The TSC will oversee the timely analysis, writing up and publication of the main trial results. The independent members of the TSC will have the opportunity to read and comment on the proposed main publications of trial data prior to submission and abstracts and presentations during the trial. This review may be concurrent to that of the trial investigators and DMC. |
| **The information about the TSC that will be included in published trial reports** | TSC members will be named and their affiliations listed in the main report, unless they explicitly request otherwise. |
| **Any constraints on TSC members divulging information about their deliberations after the trial has been published** | The TSC may discuss issues from their involvement in the trial 12 months after the primary trial results have been published, or sooner if permission is agreed with the other trial committees and trials office. Similarly, the TSC will decide when it is appropriate for TMG and DMC members to trade in related stocks. |
Figure 1: Trial Design

Pre-screening

Consent and baseline assessments (VISITS 0, 1 & 2)*
(UK n = 40, Canada n = 40)

Randomisation

Standard care UK n = 20, Canada n = 20

Low energy diet incorporating phased meal replacement plan combined with exercise training UK n=20, Canada n = 20

Dietary Support Weeks 1 through 12
Initial meeting with study dietitian for intervention planning in week 0 with core follow-on support provided in weeks 1, 2, 4, 8

Exercise Support Weeks 3 through 12
Structured exercise sessions three times per week, at least two of which directly supervised

Clinical review (Baseline, week 1, 2, 4, 8)
*Blood pressure, glucose and weight
*Antihyperglycemics and antihypertensives withdrawn at week 0; reintroduced/rewithdrawn as clinically needed

Week 12 intermediate outcome assessments (VISIT 3)*
*Baseline, week 12 and week 24 visits include: HbA1c, accelerometer monitoring, resting energy expenditure, DXA scan, weight, neck and waist circumference, urine sample, blood pressure, fasting glucose, lipids, BMI, maximal exercise test, short physical performance battery, food diary, questionnaires; only baseline and final assessments include MRI

Week 24 final outcome assessments (VISITS 4 & 5)*
Exit consultation with dietitian, exercise specialist, study physician(s)

Control group offered the 12 week low energy diet and meal replacement plan, followed by a 4-week food reintroduction period

Dietary Support weeks 12-24
Core dietary support sessions
Week 12, 14, 16, 18 & 21

Exercise Support weeks 12-24
Core exercise support sessions
Week 12, 14, 16, 18 & 21

Clinical review weeks 12-24
Week 12, 14, 18

Tapering of meal replacement plan and 'relapse management'
Weeks 13-24

Tapered exercise supervision and 'relapse management'
Weeks 13-24

Process evaluation with intervention

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on the information supplied or contained within this supplemental material which has been supplied by the author(s).
Annex 1: Agreement and competing interests form for independent members

RESET FOR REMISSION TRIAL: Agreement to join the Trial Steering Committee as an independent member and disclosure of potential competing interests

Please complete the following document and return to the Trials Office

(Please initial box to agree)

- I have read and understood the TSC Charter version 1.0, dated (will insert date pending REB approval)
- I agree to join the Trial Steering Committee for this trial as an independent member
- I agree to treat all sensitive trial data and discussions confidentially

The avoidance of any perception that independent members of a TSC may be biased in some fashion is important for the credibility of the decisions made by the TSC and for the integrity of the trial.

Potential competing interests should be disclosed via the trials office. In many cases simple disclosure up front should be sufficient. Otherwise, the (potential) independent TSC member should remove the conflict or stop participating in the TSC. Table 1 lists potential competing interests.

- No, I have no potential competing interests to declare
- Yes, I have potential competing interests to declare (please detail below)

Please provide details of any potential competing interests:

____________________________________________________________________________________

____________________________________________________________________________________

Name: ________________________________  Date: ______________

Signed: __________________________

Table 1: Potential competing interests for independent members

- Stock ownership in any commercial companies involved
- Stock transaction in any commercial company involved (if previously holding stock)
- Consulting arrangements with the Sponsor/Funder
- Ongoing advisory role to a company providing products to the trial
- Frequent speaking engagements on behalf of the intervention
- Career tied up in a product or technique assessed by trial
- Hands-on participation in the trial
- Involvement in the running of the trial
- Emotional involvement in the trial
- Intellectual conflict e.g., strong prior belief in the trial’s experimental arm
- Involvement in regulatory issues relevant to the trial procedures
- Investment (financial or intellectual) or career tied up in competing products
Annex 2: Agreement and competing interests form for non-independent members

RESET FOR REMISSION TRIAL: Agreement to join the Trial Steering Committee as a non-independent member and disclosure of potential competing interests

Please complete the following document and return to the Trials Office.

(Please initial box to agree)

☐ I have read and understood the TSC Charter version 1.0, dated 24th April 2013

☐ I agree to join the Trial Steering Committee for this trial as a non-independent member

☐ I agree to treat all sensitive trial data and discussions confidentially

The avoidance of any perception that members of a TSC may be biased in some undisclosed fashion is important for the credibility of the decisions made by the TSC and for the integrity of the trial.

Possible competing interests should be disclosed via the trials office. In many cases simple disclosure up front should be sufficient. Otherwise, the (potential) independent TSC member should remove the conflict or stop participating in the TSC. Table 1 lists potential competing interests.

☐ No, I have no competing interests to declare other than involvement in the trial

☐ Yes, I have competing interests to declare (please detail below)

Please provide details of any competing interests:

________________________________________________________________________

________________________________________________________________________

Name: __________________________

Signed: __________________________    Date: ______________

Table 1: Potential competing interests for non-independent members

- Stock ownership in any commercial companies involved
- Stock transaction in any commercial company involved (if previously holding stock)
- Consulting arrangements with the Sponsor/Funder
- Ongoing advisory role to a company providing drugs to the trial
- Frequent speaking engagements on behalf of the intervention
- Intellectual conflict e.g., strong prior belief in the trial’s experimental arm
- Involvement in regulatory issues relevant to the trial procedures
Annex 3: Agreement and confidentiality agreement for observers

RESET FOR REMISSION TRIAL: Agreement to attend the Trial Steering Committee and treat all information confidentially

Please complete the following document and return to the Trials Office.

(Please initial box to agree)

☐ I have received a copy of the TSC Charter version 1.0 dated 24th April 2013

☐ I agree to attend the Trial Steering Committee meeting on ___/___/____

☐ I agree to treat as confidential any sensitive information gained during this meeting unless explicitly permitted

Name: ___________________________  
Signed: ___________________________  Date: ______________

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
Annex 4: Document History

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Who</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>24 April 2013</td>
<td>DM</td>
<td>First draft</td>
</tr>
</tbody>
</table>